Expression	O
and	O
role	O
of	O
PML	B-DNA
gene	I-DNA
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B-protein
and	I-protein
Rb	I-protein
proteins	I-protein
in	O
erythropoiesis	O
.	O

The	O
expression	O
of	O
the	O
PML	B-DNA
gene	I-DNA
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPCs	B-cell_type
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O

PML	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	B-cell_type
,	O
are	O
consistently	O
induced	O
by	O
growth	B-protein
factor	I-protein
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O

Thereafter	O
,	O
PML	B-protein
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

In	O
functional	O
studies	O
,	O
PML	B-protein
expression	O
was	O
inhibited	O
by	O
addition	O
of	O
antisense	O
oligomers	O
targeting	O
PML	B-RNA
mRNA	I-RNA
(	O
alpha-PML	B-protein
)	O
.	O

Interestingly	O
,	O
early	O
treatment	O
(	O
day	O
0	O
HPCs	B-cell_type
)	O
with	O
alpha-PML	B-protein
reduced	O
the	O
number	O
of	O
both	O
erythroid	B-cell_line
and	I-cell_line
granulocytic	I-cell_line
colonies	I-cell_line
,	O
whereas	O
late	O
treatment	O
(	O
day	O
5	O
culture	O
)	O
reduced	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
,	O
clonogenesis	O
.	O

These	O
findings	O
suggest	O
that	O
PML	B-protein
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O

The	O
pattern	O
of	O
PML	B-protein
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	B-cell_type
pRb	B-protein
105	I-protein
.	O

Combined	O
treatment	O
of	O
HPCs	B-cell_type
with	O
alpha-PML	B-protein
and	O
alpha-Rb	O
oligomers	O
inhibited	O
both	O
PML	O
and	O
Rb	O
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O

Furthermore	O
,	O
PML	B-protein
and	O
pRb	B-protein
105	I-protein
were	O
co-immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	B-cell_type
precursors	I-cell_type
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	B-protein
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	B-protein
with	O
pRb	B-protein
105	I-protein
.	O

Oncogene	NULL
(	NULL
1999	NULL
)	NULL
18	NULL
,	NULL
3529-3540	NULL
©	NULL
1999	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/99	NULL
$	NULL
12.00	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

stockton-press.co.uk/onc	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
gene	NULL
in	NULL
normal	NULL
adult	NULL
hematopoiesis	NULL
:	NULL
functional	NULL
interaction	NULL
between	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
'	NULL
,	NULL
M	NULL
Valtieri	NULL
'	NULL
,	NULL
F	NULL
Grignani	NULL
'	NULL
,	NULL
R	NULL
Puglisi	NULL
'	NULL
,	NULL
L	NULL
Luchetti	NULL
,	NULL
B	NULL
Masella®	NULL
,	NULL
M	NULL
Alcalay*	NULL
,	NULL
U	NULL
Testa	NULL
'	NULL
and	NULL
C	NULL
Peschle*	NULL
``	NULL
>	NULL
'Department	NULL
of	NULL
Hematology	NULL
and	NULL
Oncology	NULL
,	NULL
Istituto	NULL
Superiore	NULL
di	NULL
Sanita	NULL
,	NULL
Rome	NULL
,	NULL
Italy	NULL
;	NULL
``	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
,	NULL
Kimmel	NULL
Cancer	NULL
Center	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pennsylvania	NULL
,	NULL
USA	NULL
;	NULL
*Department	NULL
of	NULL
Clinical	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Perugia	NULL
,	NULL
Perugia	NULL
,	NULL
Italy	NULL
;	NULL
*Department	NULL
of	NULL
Experimental	NULL
Oncology	NULL
,	NULL
European	NULL
Institute	NULL
of	NULL
Oncology	NULL
,	NULL
Milan	NULL
,	NULL
Italy	NULL
The	NULL
expression	NULL
of	NULL
the	NULL
PML	NULL
gene	NULL
was	NULL
investigated	NULL
in	NULL
purified	NULL
early	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
(	NULL
HPCs	NULL
)	NULL
induced	NULL
to	NULL
unilineage	NULL
erythroid	NULL
or	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

PML	NULL
mRNA	NULL
and	NULL
protein	NULL
,	NULL
while	NULL
barely	NULL
detectable	NULL
in	NULL
quiescent	NULL
HPCs	NULL
,	NULL
are	NULL
consistently	NULL
induced	NULL
by	NULL
growth	NULL
factor	NULL
stimulation	NULL
through	NULL
the	NULL
erythroid	NULL
or	NULL
granulocytic	NULL
lineage	NULL
.	NULL

Thereafter	NULL
,	NULL
PML	NULL
is	NULL
downmodulated	NULL
in	NULL
late	NULL
granulocytic	NULL
maturation	NULL
,	NULL
whereas	NULL
it	NULL
is	NULL
sustainably	NULL
expressed	NULL
through	NULL
the	NULL
erythroid	NULL
pathway	NULL
.	NULL

In	NULL
functional	NULL
studies	NULL
,	NULL
PML	NULL
expression	NULL
was	NULL
inhibited	NULL
by	NULL
addition	NULL
of	NULL
antisense	NULL
oligomers	NULL
targeting	NULL
PML	NULL
mRNA	NULL
(	NULL
«	NULL
-PML	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
early	NULL
treatment	NULL
(	NULL
day	NULL
0	NULL
HPCs	NULL
)	NULL
with	NULL
«	NULL
-PML	NULL
reduced	NULL
the	NULL
number	NULL
of	NULL
both	NULL
erythroid	NULL
and	NULL
granulocytic	NULL
colonies	NULL
,	NULL
whereas	NULL
late	NULL
treatment	NULL
(	NULL
day	NULL
5	NULL
culture	NULL
)	NULL
reduced	NULL
erythroid	NULL
,	NULL
but	NULL
not	NULL
granulocytic	NULL
,	NULL
clono-genesis	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
PML	NULL
is	NULL
required	NULL
for	NULL
early	NULL
hematopoiesis	NULL
and	NULL
erythroid	NULL
,	NULL
but	NULL
not	NULL
granulocytic	NULL
maturation	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
PML	NULL
expression	NULL
in	NULL
normal	NULL
hematopoiesis	NULL
mimics	NULL
that	NULL
of	NULL
retinoblastoma	NULL
pRb	NULL
105	NULL
.	NULL

Combined	NULL
treatment	NULL
of	NULL
HPCs	NULL
with	NULL
«	NULL
-PML	NULL
and	NULL
«	NULL
-Rb	NULL
oligomers	NULL
inhibited	NULL
both	NULL
PML	NULL
and	NULL
Rb	NULL
protein	NULL
expression	NULL
and	NULL
completely	NULL
blocked	NULL
erythroid	NULL
colony	NULL
development	NULL
.	NULL

Furthermore	NULL
,	NULL
PML	NULL
and	NULL
pRb	NULL
105	NULL
were	NULL
co-immunopreci-pitated	NULL
in	NULL
cellular	NULL
lysates	NULL
derived	NULL
from	NULL
-	NULL
erythroid	NULL
precursors	NULL
indicating	NULL
that	NULL
this	NULL
functional	NULL
interaction	NULL
may	NULL
have	NULL
a	NULL
biochemical	NULL
basis	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
a	NULL
key	NULL
functional	NULL
role	NULL
of	NULL
PML	NULL
in	NULL
early	NULL
hematopoiesis	NULL
and	NULL
late	NULL
erythropoiesis	NULL
:	NULL
the	NULL
latter	NULL
phenomenon	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
molecular	NULL
and	NULL
functional	NULL
interaction	NULL
of	NULL
PML	NULL
with	NULL
pRb	NULL
105	NULL
.	NULL

Keywords	NULL
:	NULL
HPCs	NULL
;	NULL
PML	NULL
;	NULL
RB	NULL
;	NULL
erythropoiesis	NULL
Introduction	NULL
Hematopoiesis	NULL
involves	NULL
the	NULL
coordinate	NULL
activation	NULL
of	NULL
genetic	NULL
programs	NULL
that	NULL
control	NULL
the	NULL
processes	NULL
of	NULL
lineage	NULL
commitment	NULL
and	NULL
maturation	NULL
(	NULL
Shivdasani	NULL
and	NULL
Orkin	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
genes	NULL
that	NULL
take	NULL
part	NULL
in	NULL
chromosome	NULL
rearrangements	NULL
of	NULL
human	NULL
acute	NULL
leukemias	NULL
are	NULL
most	NULL
likely	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
differentiation	NULL
and	NULL
prolifera-tion	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
genes	NULL
are	NULL
important	NULL
regulators	NULL
of	NULL
normal	NULL
hematopoiesis	NULL
(	NULL
Sawyers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Rabbitts	NULL
*Correspondence	NULL
:	NULL
C	NULL
Peschle	NULL
,	NULL
T	NULL
Jefferson	NULL
University	NULL
,	NULL
Kimmel	NULL
Center	NULL
,	NULL
Bluemle	NULL
Life	NULL
Science	NULL
Building	NULL
,	NULL
233	NULL
South	NULL
10th	NULL
Street	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
19107-5541	NULL
,	NULL
USA	NULL
Received	NULL
26	NULL
May	NULL
1998	NULL
;	NULL
revised	NULL
5	NULL
November	NULL
1998	NULL
;	NULL
accepted	NULL
13	NULL
January	NULL
1999	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
,	NULL
found	NULL
at	NULL
molecular	NULL
level	NULL
in	NULL
over	NULL
95	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
,	NULL
involves	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
RAR	NULL
«	NULL
)	NULL
gene	NULL
on	NULL
chromosome	NULL
17	NULL
and	NULL
the	NULL
PML	NULL
gene	NULL
on	NULL
chromosome	NULL
15	NULL
,	NULL
generating	NULL
the	NULL
PML/	NULL
RARs	NULL
«	NULL
fusion	NULL
gene	NULL
that	NULL
encodes	NULL
fusion	NULL
proteins	NULL
(	NULL
Warrell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Grignani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
PML/RARa	NULL
«	NULL
protein	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
APL	NULL
(	NULL
Alcalay	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
PML/RAR	NULL
«	NULL
in	NULL
myeloid	NULL
cell	NULL
lines	NULL
blocks	NULL
differentiation	NULL
and	NULL
decreases	NULL
sensitivity	NULL
to	NULL
apoptotic	NULL
cell	NULL
death	NULL
(	NULL
Grignani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1995	NULL
;	NULL
Rousselot	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
develop	NULL
an	NULL
APL-like	NULL
leukemia	NULL
(	NULL
Grisolano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
He	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997b	NULL
;	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
PML	NULL
protein-dimerization	NULL
and	NULL
RAR	NULL
«	NULL
DNA	NULL
binding	NULL
domains	NULL
must	NULL
interact	NULL
to	NULL
ensure	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
PML/RAR	NULL
«	NULL
(	NULL
Perez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Grignani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
the	NULL
fusion	NULL
protein	NULL
depend	NULL
on	NULL
the	NULL
alteration	NULL
of	NULL
both	NULL
RAR	NULL
«	NULL
and	NULL
PML	NULL
function	NULL
,	NULL
the	NULL
latter	NULL
possibly	NULL
mediated	NULL
by	NULL
protein-protein	NULL
interactions	NULL
(	NULL
Grignani	NULL
ef	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

A	NULL
role	NULL
in	NULL
normal	NULL
hematopoietic	NULL
differentiation	NULL
has	NULL
been	NULL
established	NULL
for	NULL
RAR	NULL
«	NULL
(	NULL
Kastner	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
;	NULL
however	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
physiological	NULL
function	NULL
of	NULL
PML	NULL
.	NULL

Ablation	NULL
of	NULL
murine	NULL
PML	NULL
protein	NULL
by	NULL
homologous	NULL
recombination	NULL
revealed	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
PML	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
hematopoietic	NULL
precursors	NULL
,	NULL
possibly	NULL
mediated	NULL
via	NULL
interaction	NULL
with	NULL
the	NULL
RA	NULL
pathway	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
study	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
and	NULL
role	NULL
in	NULL
normal	NULL
hematopoiesis	NULL
is	NULL
relevant	NULL
for	NULL
the	NULL
comprehension	NULL
of	NULL
both	NULL
the	NULL
pathogenesis	NULL
of	NULL
APL	NULL
and	NULL
the	NULL
physiology	NULL
of	NULL
hematopoiesis	NULL
.	NULL

PML	NULL
is	NULL
a	NULL
phosphoprotein	NULL
associated	NULL
with	NULL
the	NULL
nuclear	NULL
matrix	NULL
and	NULL
expressed	NULL
in	NULL
most	NULL
tissues	NULL
(	NULL
Daniel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Chang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

It	NULL
belongs	NULL
to	NULL
a	NULL
large	NULL
family	NULL
of	NULL
proteins	NULL
with	NULL
common	NULL
structural	NULL
features	NULL
,	NULL
including	NULL
a	NULL
RING	NULL
motif	NULL
,	NULL
two	NULL
additional	NULL
Cys/His-rich	NULL
regions	NULL
,	NULL
named	NULL
B-boxes	NULL
and	NULL
a	NULL
coiled	NULL
coil	NULL
region	NULL
,	NULL
through	NULL
which	NULL
PML	NULL
is	NULL
able	NULL
to	NULL
form	NULL
homodimers	NULL
and	NULL
,	NULL
in	NULL
APL	NULL
cells	NULL
,	NULL
heterodimers	NULL
with	NULL
PML/RAR	NULL
(	NULL
Kastner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Goddard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Reddy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Borden	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
nucleus	NULL
,	NULL
the	NULL
PML	NULL
protein	NULL
is	NULL
mainly	NULL
localized	NULL
in	NULL
specific	NULL
subdomains	NULL
,	NULL
the	NULL
PML	NULL
nuclear	NULL
bodies	NULL
(	NULL
PML-NBs	NULL
)	NULL
(	NULL
Dyck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
APL	NULL
cells	NULL
the	NULL
PML-NBs	NULL
are	NULL
disrupted	NULL
and	NULL
PML	NULL
colocalizes	NULL
with	NULL
PML/RARa	NULL
in	NULL
novel	NULL
structures	NULL
called	NULL
microspeckles	NULL
(	NULL
Dyck	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Koken	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Weis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
delocalization	NULL
of	NULL
PML	NULL
by	NULL
PML-RAR	NULL
«	NULL
,	NULL
is	NULL
associated	NULL
with	NULL
cellular	NULL
transformation	NULL
and	NULL
can	NULL
be	NULL
reversed	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
RA	NULL
,	NULL
that	NULL
induces	NULL
reaggregation	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
3530	NULL
of	NULL
PML-NBs	NULL
,	NULL
and	NULL
cellular	NULL
differentiation	NULL
(	NULL
Dyck	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Koken	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Weis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
APL	NULL
patients	NULL
achieve	NULL
clinical	NULL
remission	NULL
after	NULL
all-trans	NULL
RA	NULL
therapy	NULL
(	NULL
Huang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Castaigne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Warrell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
integrity	NULL
of	NULL
the	NULL
PML	NULL
function	NULL
is	NULL
required	NULL
in	NULL
normal	NULL
hematopoiesis	NULL
and	NULL
that	NULL
protein-protein	NULL
interactions	NULL
occurring	NULL
within	NULL
the	NULL
PML	NULL
NBs	NULL
are	NULL
relevant	NULL
for	NULL
normal	NULL
hematopoietic	NULL
differentiation	NULL
.	NULL

The	NULL
disruption	NULL
of	NULL
PML	NULL
NBs	NULL
is	NULL
also	NULL
caused	NULL
by	NULL
cytomegalovirus	NULL
(	NULL
Ahn	NULL
and	NULL
Hayward	NULL
,	NULL
1997	NULL
)	NULL
,	NULL
herpes	NULL
virus	NULL
(	NULL
Everett	NULL
and	NULL
Maul	NULL
,	NULL
1994	NULL
;	NULL
Everett	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
and	NULL
adenovirus	NULL
infection	NULL
(	NULL
Doucas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
interaction	NULL
of	NULL
viral	NULL
proteins	NULL
with	NULL
the	NULL
PML	NULL
NB	NULL
protein	NULL
complexes	NULL
(	NULL
Ahn	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
biological	NULL
activity	NULL
of	NULL
PML	NULL
is	NULL
still	NULL
under	NULL
investigation	NULL
.	NULL

PML	NULL
has	NULL
been	NULL
regarded	NULL
as	NULL
a	NULL
growth	NULL
regulator	NULL
(	NULL
Mu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
He	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997a	NULL
;	NULL
Guiochon-Mantel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
when	NULL
overexpressed	NULL
,	NULL
it	NULL
suppresses	NULL
:	NULL
(	NULL
i	NULL
)	NULL
anchorage-independent	NULL
growth	NULL
of	NULL
APL-derived	NULL
NB4	NULL
cells	NULL
(	NULL
Mu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
oncogenic	NULL
transformation	NULL
of	NULL
rat	NULL
embryonic	NULL
fibroblasts	NULL
by	NULL
cooperative	NULL
oncogenes	NULL
and	NULL
of	NULL
NIH3T3	NULL
cells	NULL
by	NULL
activated	NULL
Neu	NULL
(	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
growth	NULL
and	NULL
tumorigenicity	NULL
of	NULL
prostate	NULL
cancer	NULL
cells	NULL
(	NULL
He	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997a	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
PML	NULL
shares	NULL
many	NULL
properties	NULL
with	NULL
tumor	NULL
suppressors	NULL
.	NULL

The	NULL
molecular	NULL
pathway	NULL
through	NULL
which	NULL
PML	NULL
exerts	NULL
its	NULL
function	NULL
remains	NULL
unknown	NULL
,	NULL
although	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
PML	NULL
can	NULL
act	NULL
as	NULL
a	NULL
transcription	NULL
coregulator	NULL
(	NULL
Guiochon-Mantel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
PML	NULL
protein	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
normal	NULL
hematopoiesis	NULL
as	NULL
suggested	NULL
by	NULL
its	NULL
role	NULL
in	NULL
cell	NULL
growth	NULL
control	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Mu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
gene	NULL
transcription	NULL
block	NULL
in	NULL
APL	NULL
(	NULL
Grignani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Daniel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
PML	NULL
gene	NULL
expression	NULL
and	NULL
function	NULL
in	NULL
highly	NULL
purified	NULL
human	NULL
adult	NULL
HPCs	NULL
induced	NULL
to	NULL
proliferate	NULL
and	NULL
differentiate	NULL
to	NULL
terminal	NULL
stages	NULL
along	NULL
the	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
or	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
lineage	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
PML	NULL
expression	NULL
is	NULL
regulated	NULL
during	NULL
normal	NULL
hematopoiesis	NULL
in	NULL
a	NULL
differentiation	NULL
and	NULL
lineage-dependent	NULL
manner	NULL
and	NULL
is	NULL
required	NULL
in	NULL
early	NULL
hematopoiesis	NULL
and	NULL
E	NULL
,	NULL
but	NULL
not	NULL
G	NULL
,	NULL
maturation	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
PML	NULL
expression	NULL
in	NULL
HPCs	NULL
resembles	NULL
that	NULL
of	NULL
pRb	NULL
105	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

pRb	NULL
105	NULL
may	NULL
exert	NULL
its	NULL
biological	NULL
functions	NULL
by	NULL
interacting	NULL
with	NULL
other	NULL
proteins	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996a	NULL
,	NULL
b	NULL
)	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
viral	NULL
proteins	NULL
which	NULL
are	NULL
implicated	NULL
in	NULL
PML-NB	NULL
disruption	NULL
during	NULL
infection	NULL
(	NULL
Nevins	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
we	NULL
show	NULL
that	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
functionally	NULL
and	NULL
physically	NULL
interact	NULL
in	NULL
erythropoiesis	NULL
.	NULL

Results	NULL
Expression	NULL
of	NULL
PML	NULL
mRNA	NULL
in	NULL
HPC	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
or	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
cultures	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
a	NULL
purification	NULL
procedure	NULL
for	NULL
early	NULL
HPCs	NULL
from	NULL
adult	NULL
peripheral	NULL
blood	NULL
.	NULL

The	NULL
Step	NULL
IIIP	NULL
cell	NULL
population	NULL
obtained	NULL
by	NULL
this	NULL
procedure	NULL
(	NULL
CFU-GEMM	NULL
,	NULL
BFU-E	NULL
and	NULL
CFU-GM	NULL
)	NULL
is	NULL
characterized	NULL
by	NULL
>	NULL
90	NULL
%	NULL
CD34*	NULL
cells	NULL
and	NULL
90-95	NULL
%	NULL
HPC	NULL
frequency	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
FCS-	NULL
liquid	NULL
suspension	NULL
culture	NULL
,	NULL
these	NULL
cells	NULL
undergo	NULL
selective	NULL
proliferation	NULL
and	NULL
differentiation	NULL
along	NULL
the	NULL
erythroid	NULL
pathway	NULL
,	NULL
upon	NULL
addition	NULL
of	NULL
very	NULL
low	NULL
amounts	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
and	NULL
a	NULL
saturating	NULL
level	NULL
of	NULL
Epo	NULL
,	NULL
or	NULL
for	NULL
the	NULL
granulopoietic	NULL
neutrophilic	NULL
lineage	NULL
,	NULL
upon	NULL
addition	NULL
of	NULL
low-dose	NULL
IL-3+GM-CSF	NULL
and	NULL
saturating	NULL
G-CSF	NULL
level	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
the	NULL
first	NULL
week	NULL
of	NULL
culture	NULL
,	NULL
HPCs	NULL
show	NULL
a	NULL
high	NULL
proliferative	NULL
activity	NULL
which	NULL
is	NULL
associated	NULL
with	NULL
their	NULL
progressive	NULL
differentiation	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
progressive	NULL
decline	NULL
of	NULL
CD34*	NULL
cells	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

In	NULL
the	NULL
second	NULL
week	NULL
we	NULL
observed	NULL
the	NULL
disappearance	NULL
of	NULL
CD34*	NULL
and	NULL
blasts	NULL
and	NULL
the	NULL
progressively	NULL
increasing	NULL
expression	NULL
of	NULL
specific	NULL
membrane	NULL
markers	NULL
for	NULL
E	NULL
and	NULL
G	NULL
precursors	NULL
(	NULL
e.g	NULL
.	NULL

glycophorin	NULL
A	NULL
and	NULL
CD15	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
;	NULL
cell	NULL
morphology	NULL
analysis	NULL
showed	NULL
a	NULL
gradual	NULL
wave	NULL
of	NULL
maturation	NULL
along	NULL
the	NULL
E	NULL
and	NULL
G	NULL
pathway	NULL
to	NULL
terminal	NULL
cells	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
at	NULL
day	NULL
14	NULL
,	NULL
97+2	NULL
%	NULL
erythroid	NULL
cells	NULL
(	NULL
largely	NULL
orthochromatic	NULL
normo-blasts	NULL
)	NULL
in	NULL
E	NULL
cultures	NULL
,	NULL
and	NULL
~98	NULL
%	NULL
granulopoietic	NULL
cells	NULL
in	NULL
G	NULL
culture	NULL
(	NULL
largely	NULL
mature	NULL
neutrophils	NULL
)	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
expression	NULL
of	NULL
PML	NULL
mRNA	NULL
in	NULL
differentiating	NULL
HPCs	NULL
,	NULL
RNA	NULL
samples	NULL
were	NULL
generated	NULL
at	NULL
sequential	NULL
days	NULL
from	NULL
Step	NULL
IIIP	NULL
HPCs	NULL
differentiating	NULL
along	NULL
the	NULL
E	NULL
or	NULL
G	NULL
pathway	NULL
.	NULL

Three	NULL
independent	NULL
RT	NULL
PCR	NULL
experiments	NULL
were	NULL
performed	NULL
.	NULL

A	NULL
series	NULL
of	NULL
controls	NULL
,	NULL
including	NULL
dose-response	NULL
curves	NULL
for	NULL
the	NULL
assayed	NULL
templates	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
ensured	NULL
a	NULL
semiquantitative	NULL
evaluation	NULL
of	NULL
mRNA	NULL
levels	NULL
(	NULL
representative	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
2a	NULL
)	NULL
.	NULL

PML	NULL
mRNA	NULL
,	NULL
is	NULL
barely	NULL
expressed	NULL
in	NULL
quiescent	NULL
HPCs	NULL
and	NULL
is	NULL
rapidly	NULL
induced	NULL
through	NULL
the	NULL
first	NULL
week	NULL
of	NULL
culture	NULL
in	NULL
both	NULL
E	NULL
and	NULL
G	NULL
culture	NULL
.	NULL

In	NULL
the	NULL
second	NULL
week	NULL
,	NULL
high	NULL
levels	NULL
of	NULL
PML-mRNA	NULL
expression	NULL
are	NULL
sustained	NULL
through	NULL
terminal	NULL
maturation	NULL
(	NULL
days	NULL
7-13	NULL
)	NULL
in	NULL
the	NULL
E	NULL
pathway	NULL
.	NULL

In	NULL
the	NULL
G	NULL
lineage	NULL
,	NULL
PML-mRNA	NULL
expression	NULL
is	NULL
down-regulated	NULL
at	NULL
early	NULL
granulopoietic	NULL
precursor	NULL
stage	NULL
(	NULL
days	NULL
7-11	NULL
of	NULL
culture	NULL
)	NULL
and	NULL
is	NULL
virtually	NULL
abolished	NULL
through	NULL
terminal	NULL
maturation	NULL
(	NULL
day	NULL
13	NULL
)	NULL
(	NULL
Figure	NULL
2a	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
PML	NULL
protein	NULL
in	NULL
differentiating	NULL
HPC	NULL
cultures	NULL
We	NULL
then	NULL
monitored	NULL
the	NULL
kinetics	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
.	NULL

In	NULL
differentiating	NULL
HPCs	NULL
,	NULL
an	NULL
anti-PML	NULL
mAb	NULL
labeled	NULL
nuclear	NULL
structures	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Flenghi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
for	NULL
PML	NULL
NBs	NULL
(	NULL
Figure	NULL
2b	NULL
and	NULL
c	NULL
)	NULL
.	NULL

At	NULL
day	NULL
0	NULL
,	NULL
quiescent	NULL
HPCs	NULL
displayed	NULL
low	NULL
nuclear	NULL
PML	NULL
expression	NULL
.	NULL

Initial	NULL
differentiation	NULL
of	NULL
HPCs	NULL
along	NULL
the	NULL
E	NULL
or	NULL
G	NULL
pathway	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
marked	NULL
induction	NULL
of	NULL
PML	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
increase	NULL
of	NULL
fluorescence	NULL
staining	NULL
(	NULL
Figure	NULL
2b	NULL
and	NULL
c	NULL
,	NULL
day	NULL
5	NULL
)	NULL
.	NULL

In	NULL
the	NULL
second	NULL
week	NULL
,	NULL
PML	NULL
expression	NULL
was	NULL
still	NULL
elevated	NULL
in	NULL
differentiating	NULL
E	NULL
culture	NULL
(	NULL
days	NULL
7-11	NULL
)	NULL
(	NULL
Figure	NULL
2b	NULL
)	NULL
abruptly	NULL
declines	NULL
in	NULL
G	NULL
culture	NULL
after	NULL
day	NULL
9	NULL
and	NULL
almost	NULL
completely	NULL
disappears	NULL
in	NULL
mature	NULL
granulopoietic	NULL
cells	NULL
(	NULL
G	NULL
,	NULL
day	NULL
13	NULL
)	NULL
(	NULL
Figure	NULL
2¢	NULL
)	NULL
.	NULL

PML	NULL
protein	NULL
expression	NULL
during	NULL
E	NULL
and	NULL
G	NULL
differentiation	NULL
was	NULL
quantitated	NULL
by	NULL
counting	NULL
the	NULL
number	NULL
of	NULL
PODs	NULL
detected	NULL
by	NULL
immunofluorescence	NULL
staining	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

This	NULL
analysis	NULL
showed	NULL
that	NULL
the	NULL
number	NULL
of	NULL
PODs	NULL
peaks	NULL
at	NULL
days	NULL
3-5	NULL
in	NULL
G	NULL
cultures	NULL
and	NULL
at	NULL
days	NULL
5-7	NULL
in	NULL
E	NULL
cultures	NULL
;	NULL
at	NULL
later	NULL
times	NULL
of	NULL
culture	NULL
although	NULL
the	NULL
number	NULL
of	NULL
PODs	NULL
per	NULL
cell	NULL
declines	NULL
both	NULL
in	NULL
E	NULL
and	NULL
G	NULL
cells	NULL
,	NULL
this	NULL
phenomenon	NULL
is	NULL
much	NULL
more	NULL
pronounced	NULL
in	NULL
the	NULL
G	NULL
lineage	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

(	NULL
E	NULL
100	NULL
coas	NULL
%	NULL
of	NULL
Total	NULL
40	NULL
20	NULL
%	NULL
of	NULL
Total	NULL
0	NULL
§	NULL
7	NULL
10	NULL
12	NULL
Days	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
Blasts+Myelob	NULL
.	NULL

Promyeto	NULL
.	NULL

Myelo	NULL
.	NULL

Metamyelo	NULL
.	NULL

BandGranulo	NULL
.	NULL

Monocytes	NULL
Days	NULL
Figure	NULL
1	NULL
-	NULL
Cell	NULL
morphology	NULL
and	NULL
membrane	NULL
differentiation	NULL
markers	NULL
in	NULL
E	NULL
and	NULL
G	NULL
unilineage	NULL
cultures	NULL
of	NULL
purified	NULL
Step	NULL
III	NULL
P	NULL
HPCs	NULL
,	NULL
as	NULL
evaluated	NULL
at	NULL
sequential	NULL
days	NULL
.	NULL

The	NULL
morphology	NULL
of	NULL
erythroid	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
was	NULL
classified	NULL
according	NULL
to	NULL
progressive	NULL
stages	NULL
which	NULL
include	NULL
:	NULL
(	NULL
i	NULL
)	NULL
for	NULL
the	NULL
E	NULL
series	NULL
blasts	NULL
,	NULL
proerythroblasts	NULL
(	NULL
pro	NULL
.	NULL
)	NULL

basophilic	NULL
erythroblasts	NULL
(	NULL
Baso	NULL
.	NULL

Erythr	NULL
.	NULL
)	NULL

,	NULL
polychromatophilic	NULL
erythroblasts	NULL
(	NULL
Poly	NULL
.	NULL
)	NULL

and	NULL
orthochromatic	NULL
erythroblasts	NULL
(	NULL
ortho	NULL
.	NULL
)	NULL

;	NULL
for	NULL
the	NULL
G	NULL
series	NULL
,	NULL
blasts	NULL
,	NULL
myeloblasts	NULL
(	NULL
myelob	NULL
.	NULL
)	NULL

,	NULL
promyelocytes	NULL
(	NULL
promyelo	NULL
.	NULL
)	NULL

,	NULL
metamyelocytes	NULL
(	NULL
metamyelo	NULL
.	NULL
)	NULL

,	NULL
band	NULL
granulocytes	NULL
(	NULL
band	NULL
granulo	NULL
.	NULL
)	NULL

To	NULL
confirm	NULL
these	NULL
data	NULL
,	NULL
we	NULL
performed	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
HPCs	NULL
harvested	NULL
at	NULL
day	NULL
9	NULL
and	NULL
day	NULL
12	NULL
of	NULL
E	NULL
or	NULL
G	NULL
cultures	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
Nason-Burchenal	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
the	NULL
PG-M3	NULL
mAb	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
PML	NULL
proteins	NULL
(	NULL
Flenghi	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
recognizes	NULL
several	NULL
PML	NULL
isoforms	NULL
,	NULL
originated	NULL
by	NULL
differential	NULL
mRNA	NULL
splicing	NULL
(	NULL
Fagioli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
with	NULL
bands	NULL
of	NULL
90	NULL
and	NULL
70	NULL
K	NULL
,	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

PML	NULL
protein	NULL
was	NULL
abundant	NULL
in	NULL
day	NULL
9	NULL
and	NULL
12	NULL
erythroblasts	NULL
,	NULL
whereas	NULL
it	NULL
was	NULL
sharply	NULL
downmodulated	NULL
in	NULL
granulopoietic	NULL
precursors	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
one	NULL
of	NULL
the	NULL
PML	NULL
isoforms	NULL
we	NULL
used	NULL
a	NULL
U937	NULL
cell	NULL
line	NULL
clone	NULL
stably	NULL
transfected	NULL
with	NULL
a	NULL
PML3	NULL
cDNA	NULL
(	NULL
Flenghi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Overall	NULL
,	NULL
protein	NULL
data	NULL
strictly	NULL
paralleled	NULL
mRNA	NULL
expression	NULL
.	NULL

Effect	NULL
of	NULL
PML	NULL
antisense	NULL
oligodeoxynucleotide	NULL
on	NULL
HPC	NULL
E	NULL
and	NULL
G	NULL
colony	NULL
formation	NULL
We	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
PML	NULL
in	NULL
hematopoietic	NULL
differentiation	NULL
by	NULL
inhibiting	NULL
PML	NULL
protein	NULL
expression	NULL
with	NULL
phosphorothioate	NULL
antisense	NULL
oligodeoxynucleotide	NULL
to	NULL
PML	NULL
mRNA	NULL
(	NULL
Figure	NULL
4a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Antisense	NULL
oligomers	NULL
were	NULL
added	NULL
to	NULL
differentiating	NULL
HPCs	NULL
stimulated	NULL
by	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
to	NULL
form	NULL
erythroid	NULL
(	NULL
BFU-E	NULL
)	NULL
and/or	NULL
G	NULL
(	NULL
CFU-G	NULL
)	NULL
colonies	NULL
.	NULL

Control	NULL
cultures	NULL
were	NULL
mock	NULL
treated	NULL
with	NULL
equivalent	NULL
amounts	NULL
of	NULL
the	NULL
scrambled	NULL
antisense	NULL
oligomers	NULL
.	NULL

We	NULL
have	NULL
used	NULL
Table	NULL
1	NULL
-	NULL
Mean	NULL
number	NULL
of	NULL
PML	NULL
PODs	NULL
at	NULL
different	NULL
days	NULL
in	NULL
erythroid	NULL
and	NULL
granulocytic	NULL
cultures	NULL
Time	NULL
Mean	NULL
number	NULL
of	NULL
PODs/cell	NULL
(	NULL
day	NULL
)	NULL
Erythroid	NULL
cells	NULL
Granulocytic	NULL
cells	NULL
0	NULL
2.3+1.6	NULL
2.3+1.6	NULL
3	NULL
10.1	NULL
+2	NULL
9.2	NULL
+2.3	NULL
5	NULL
19.8	NULL
+3	NULL
8.5+1.9	NULL
7	NULL
174+2.7	NULL
6+2.9	NULL
9	NULL
13.4+2.4	NULL
4.8	NULL
+	NULL
1.6	NULL
13	NULL
12.2+2.1	NULL
1.8+0.8	NULL
Values	NULL
represent	NULL
the	NULL
mean	NULL
number	NULL
+s.d	NULL
.	NULL

of	NULL
PODs	NULL
evaluated	NULL
on	NULL
at	NULL
least	NULL
200	NULL
cells	NULL
two	NULL
sets	NULL
of	NULL
phosphorothioate	NULL
antisense	NULL
PML	NULL
oligomers	NULL
in	NULL
our	NULL
experiments	NULL
.	NULL

HPCs	NULL
treated	NULL
at	NULL
day	NULL
0	NULL
showed	NULL
a	NULL
marked	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
both	NULL
E	NULL
and	NULL
G	NULL
colonies	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
.	NULL

Both	NULL
sets	NULL
of	NULL
antisense	NULL
oligomers	NULL
(	NULL
«	NULL
1-PML	NULL
,	NULL
«	NULL
2-PML	NULL
)	NULL
gave	NULL
similar	NULL
inhibitory	NULL
patterns	NULL
.	NULL

However	NULL
the	NULL
first	NULL
set	NULL
was	NULL
preferred	NULL
because	NULL
the	NULL
scrambled	NULL
«	NULL
1-PML	NULL
was	NULL
absolutely	NULL
neutral	NULL
in	NULL
our	NULL
assay	NULL
while	NULL
the	NULL
scrambled	NULL
«	NULL
2-PML	NULL
gave	NULL
~	NULL
20	NULL
%	NULL
non	NULL
specific	NULL
inhibitory	NULL
effect	NULL
.	NULL

In	NULL
addition	NULL
the	NULL
antisense	NULL
«	NULL
2-PML	NULL
was	NULL
less	NULL
efficient	NULL
in	NULL
inhibiting	NULL
both	NULL
the	NULL
E	NULL
and	NULL
the	NULL
G	NULL
cultures	NULL
than	NULL
the	NULL
antisense	NULL
«	NULL
1-PML	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
.	NULL

Treatment	NULL
at	NULL
day	NULL
5	NULL
after	NULL
growth	NULL
factor	NULL
addition	NULL
,	NULL
selectively	NULL
inhibited	NULL
E	NULL
,	NULL
but	NULL
not	NULL
G	NULL
,	NULL
colonies	NULL
(	NULL
Figure	NULL
4b	NULL
)	NULL
.	NULL

Scrambled	NULL
oligomer	NULL
«	NULL
1-PML	NULL
treatment	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
colony	NULL
formation	NULL
at	NULL
either	NULL
culture	NULL
time	NULL
(	NULL
Figure	NULL
4a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

3531	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
3532	NULL
Control	NULL
experiments	NULL
showed	NULL
that	NULL
antisense	NULL
oligomer	NULL
treatment	NULL
clearly	NULL
decreased	NULL
PML	NULL
protein	NULL
expression	NULL
in	NULL
day	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
9	NULL
in	NULL
E	NULL
and	NULL
G	NULL
cultures	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
immunofluorescence	NULL
analysis	NULL
(	NULL
Figure	NULL
Sa	NULL
and	NULL
Table	NULL
2	NULL
)	NULL
and	NULL
markedly	NULL
reduced	NULL
PML	NULL
mRNA	NULL
expression	NULL
(	NULL
€	NULL
)	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

Scrambled	NULL
oligomer	NULL
treatment	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
expression	NULL
of	NULL
either	NULL
PML	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
RNA	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

Particularly	NULL
,	NULL
IF	NULL
analysis	NULL
showed	NULL
that	NULL
antisense	NULL
oligomer	NULL
treatment	NULL
elicited	NULL
a	NULL
marked	NULL
decrease	NULL
of	NULL
the	NULL
number	NULL
of	NULL
PODs	NULL
,	NULL
while	NULL
pay	NULL
0	NULL
1	NULL
os	NULL
607	NULL
11	NULL
13	NULL
K562	NULL
(	NULL
-	NULL
)	NULL
PML	NULL
suas	NULL
<	NULL
<	NULL
|	NULL
ane	NULL
Bam	NULL
«	NULL
amen	NULL
wens	NULL
cma	NULL
camer	NULL
cece	NULL
:	NULL
ese	NULL
Day	NULL
103	NULL
§0	NULL
7	NULL
11	NULL
13	NULL
PML	NULL
[	NULL
_I	NULL
_	NULL
m	NULL
pam	NULL
Gave	NULL
cone	NULL
:	NULL
canes	NULL
Dayo	NULL
-	NULL
D336	NULL
Days	NULL
-	NULL
Day	NULL
;	NULL
Day	NULL
”	NULL
-	NULL
Day	NULL
”	NULL
,	NULL
oligomer	NULL
scrambled	NULL
treatment	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
this	NULL
parameter	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Functional	NULL
synergism	NULL
and	NULL
molecular	NULL
interaction	NULL
of	NULL
the	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
normal	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
The	NULL
described	NULL
pattern	NULL
of	NULL
PML	NULL
expression	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
previously	NULL
described	NULL
for	NULL
Rb	NULL
protein	NULL
along	NULL
the	NULL
E	NULL
and	NULL
G	NULL
lineages	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
investigated	NULL
a	NULL
possible	NULL
physical	NULL
and	NULL
functional	NULL
interaction	NULL
between	NULL
PML	NULL
and	NULL
Rb	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

«	NULL
-Rb	NULL
and	NULL
«	NULL
1-PML	NULL
oligomers	NULL
were	NULL
simultaneously	NULL
added	NULL
,	NULL
at	NULL
day	NULL
5	NULL
after	NULL
growth	NULL
factor	NULL
addition	NULL
,	NULL
to	NULL
differentiating	NULL
HPCs	NULL
induced	NULL
to	NULL
E	NULL
or	NULL
G	NULL
differentiation	NULL
.	NULL

Control	NULL
cultures	NULL
were	NULL
mock	NULL
treated	NULL
with	NULL
equivalent	NULL
amounts	NULL
of	NULL
the	NULL
scrambled	NULL
antisense	NULL
oligomers	NULL
,	NULL
«	NULL
-Rb	NULL
plus	NULL
scrambled	NULL
oligomers	NULL
or	NULL
«	NULL
1-PML	NULL
plus	NULL
scrambled	NULL
oligomers	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
both	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
was	NULL
markedly	NULL
reduced	NULL
by	NULL
this	NULL
treatment	NULL
in	NULL
both	NULL
culture	NULL
types	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
development	NULL
of	NULL
G	NULL
colonies	NULL
was	NULL
not	NULL
significantly	NULL
altered	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
whereas	NULL
very	NULL
low	NULL
doses	NULL
of	NULL
combined	NULL
«	NULL
1-PML	NULL
and	NULL
«	NULL
-Rb	NULL
oligomers	NULL
induced	NULL
a	NULL
marked	NULL
inhibition	NULL
DayO0	NULL
Day5	NULL
Day11	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
of	NULL
erythroid	NULL
colony	NULL
formation	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
this	NULL
antisense	NULL
oligomer	NULL
combination	NULL
was	NULL
more	NULL
than	NULL
additive	NULL
with	NULL
respect	NULL
to	NULL
that	NULL
of	NULL
single	NULL
«	NULL
1-PML	NULL
and	NULL
«	NULL
-	NULL
Rb	NULL
oligomers	NULL
,	NULL
indicating	NULL
a	NULL
functional	NULL
synergism	NULL
&	NULL
wl	NULL
Eo	NULL
r	NULL
oc	NULL
2	NULL
S	NULL
9	NULL
12	NULL
9	NULL
12	NULL
Day	NULL
PML	NULL
{	NULL
``	NULL
*	NULL
Sey	NULL
--	NULL
97	NULL
Figure	NULL
3	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
PML	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
HPCs	NULL
grown	NULL
for	NULL
9	NULL
or	NULL
12	NULL
days	NULL
in	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
or	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
culture	NULL
.	NULL

K562	NULL
cell	NULL
line	NULL
and	NULL
U937-PML3	NULL
the	NULL
stably	NULL
transfected	NULL
cell	NULL
line	NULL
with	NULL
PML3	NULL
cDNA	NULL
,	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
controls	NULL
.	NULL

A	NULL
representative	NULL
autoradiogram	NULL
is	NULL
shown	NULL
.	NULL

Molecular	NULL
weight	NULL
standard	NULL
corresponding	NULL
to	NULL
97	NULL
kDa	NULL
is	NULL
indicated	NULL
Day3	NULL
Day	NULL
?	NULL

Day13	NULL
Figure	NULL
2	NULL
(	NULL
a	NULL
)	NULL
PML	NULL
mRNA	NULL
expression	NULL
in	NULL
purified	NULL
HPCs	NULL
grown	NULL
in	NULL
liquid-phase	NULL
unilineage	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
or	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
cultures	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
semi-quantitative	NULL
RT-PCR	NULL
.	NULL

$	NULL
2-microglobulin	NULL
(	NULL
$	NULL
2	NULL
m	NULL
)	NULL
was	NULL
used	NULL
for	NULL
normalization	NULL
.	NULL

K562	NULL
cell	NULL
line	NULL
was	NULL
the	NULL
internal	NULL
positive	NULL
control	NULL
.	NULL

A	NULL
negative	NULL
control	NULL
(	NULL
-	NULL
)	NULL
is	NULL
also	NULL
included	NULL
.	NULL

One	NULL
representative	NULL
experiment	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Immunofluorescence	NULL
labeling	NULL
with	NULL
PG-M3	NULL
anti-PML	NULL
mAb	NULL
of	NULL
purified	NULL
HPCs	NULL
and	NULL
their	NULL
progeny	NULL
grown	NULL
in	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
or	NULL
,	NULL
(	NULL
¢	NULL
)	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
culture	NULL
,	NULL
as	NULL
evaluated	NULL
at	NULL
sequential	NULL
days	NULL
.	NULL

Fluorescent	NULL
cells	NULL
were	NULL
examined	NULL
under	NULL
a	NULL
Nikon	NULL
microphot	NULL
microscope	NULL
equipped	NULL
with	NULL
a	NULL
highly	NULL
sensitive	NULL
videocamera	NULL
and	NULL
a	NULL
digital	NULL
system	NULL
for	NULL
image	NULL
acquisition	NULL
(	NULL
x	NULL
1000	NULL
magnification	NULL
)	NULL
.	NULL

Day	NULL
11	NULL
and	NULL
day	NULL
13	NULL
granulopoietic	NULL
cells	NULL
were	NULL
overexposed	NULL
to	NULL
allow	NULL
the	NULL
detection	NULL
of	NULL
the	NULL
few	NULL
faint	NULL
PML	NULL
NBs	NULL
present	NULL
in	NULL
these	NULL
cells	NULL
3533	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
3534	NULL
a	NULL
Day	NULL
0	NULL
oligomer	NULL
addition	NULL
{	NULL
sl	NULL
BFU-E	NULL
®	NULL
BD	NULL
CR-GM	NULL
50	NULL
40	NULL
P4	NULL
6	NULL
Number	NULL
of	NULL
Colonies/200	NULL
Cells	NULL
m	NULL
$	NULL
3	NULL
c	NULL
a	NULL
R	NULL
a	NULL
Control	NULL
1	NULL
Control2	NULL
100	NULL
100	NULL
2s	NULL
so	NULL
100	NULL
109	NULL
V	NULL
Scrambled	NULL
Scrambled	NULL
«	NULL
2-PML	NULL
@	NULL
d	NULL
,	NULL
49	NULL
6	NULL
0	NULL
§	NULL
S	NULL
so	NULL
F	NULL
c	NULL
6	NULL
5	NULL
zo	NULL
&	NULL
a	NULL
E	NULL
2	NULL
10	NULL
0	NULL
Control	NULL
1	NULL
Control2	NULL
25	NULL
so	NULL
160	NULL
25	NULL
so	NULL
100	NULL
100	NULL
Z	NULL
Scrambled	NULL
Seramblod	NULL
«	NULL
i-PML	NULL
o2-PML	NULL
ai-PM	NULL
«	NULL
t-	NULL
PML	NULL
b	NULL
Day	NULL
5	NULL
oligomer	NULL
addition	NULL
150	NULL
120	NULL
_	NULL
|	NULL
O	NULL
230	NULL
%	NULL
(	NULL
e	NULL
)	NULL
]	NULL
360	NULL
oJ-PML	NULL
Figure	NULL
4	NULL
(	NULL
a	NULL
)	NULL
Treatment	NULL
of	NULL
day	NULL
0	NULL
HPCs	NULL
with	NULL
two	NULL
sets	NULL
of	NULL
phosphorothioate	NULL
oligomers	NULL
:	NULL
(	NULL
i	NULL
)	NULL
«	NULL
1-PML	NULL
or	NULL
scrambled	NULL
«	NULL
1-PML	NULL
oligomer	NULL
(	NULL
25	NULL
,	NULL
50	NULL
or	NULL
100	NULL
ug/m1	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
«	NULL
2-PML	NULL
or	NULL
scrambled	NULL
a2-PML	NULL
oligomer	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
.	NULL

Mock-treated	NULL
controls	NULL
are	NULL
also	NULL
presented	NULL
.	NULL

The	NULL
effect	NULL
on	NULL
BFU-E	NULL
and	NULL
CFU-G	NULL
colony	NULL
formation	NULL
in	NULL
semisolid	NULL
culture	NULL
induced	NULL
by	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
-	NULL
or	NULL
granulopoictic	NULL
(	NULL
G	NULL
)	NULL
-specific	NULL
HGF	NULL
stimulus	NULL
is	NULL
shown	NULL
.	NULL

Mean	NULL
values	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
,	NULL
each	NULL
performed	NULL
in	NULL
triplicate	NULL
dishes	NULL
,	NULL
are	NULL
shown	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
,	NULL
**P	NULL
<	NULL
0.01	NULL
when	NULL
compared	NULL
to	NULL
between	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
this	NULL
synergism	NULL
is	NULL
based	NULL
on	NULL
a	NULL
biochemical	NULL
interaction	NULL
of	NULL
these	NULL
two	NULL
nuclear	NULL
proteins	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
performed	NULL
reciprocal	NULL
co-immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
experiments	NULL
of	NULL
both	NULL
PML	NULL
and	NULL
pRb105	NULL
proteins	NULL
on	NULL
cell	NULL
lysates	NULL
derived	NULL
from	NULL
HPCs	NULL
at	NULL
a	NULL
late	NULL
stage	NULL
of	NULL
E	NULL
or	NULL
G	NULL
differentiation	NULL
(	NULL
days	NULL
9-11	NULL
,	NULL
Figure	NULL
7a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
HPCs	NULL
harvested	NULL
at	NULL
days	NULL
9-11	NULL
of	NULL
E	NULL
culture	NULL
,	NULL
at	NULL
day	NULL
9	NULL
of	NULL
G	NULL
culture	NULL
,	NULL
from	NULL
Rb*+	NULL
K562	NULL
cells	NULL
and	NULL
Rb-	NULL
SAOS	NULL
cells	NULL
.	NULL

Lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
either	NULL
anti-pRb105	NULL
or	NULL
anti-PML	NULL
mAb	NULL
(	NULL
Figure	NULL
7a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

The	NULL
anti-Rb	NULL
immunoprecipitate	NULL
was	NULL
loaded	NULL
onto	NULL
two	NULL
separate	NULL
8	NULL
%	NULL
SDS-PAGE	NULL
gels	NULL
and	NULL
blotted	NULL
on	NULL
membranes	NULL
.	NULL

The	NULL
two	NULL
membranes	NULL
were	NULL
probed	NULL
with	NULL
anti-pRb105	NULL
and	NULL
anti-PML	NULL
(	NULL
PG-M3	NULL
)	NULL
antibodies	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
then	NULL
revealed	NULL
by	NULL
a	NULL
chemiolumines-cence	NULL
procedure	NULL
(	NULL
Figure	NULL
7a	NULL
)	NULL
.	NULL

Results	NULL
showed	NULL
that	NULL
a	NULL
major	NULL
90	NULL
KDa	NULL
and	NULL
a	NULL
minor	NULL
70	NULL
kDa	NULL
PML	NULL
protein	NULL
co-immunoprecipitate	NULL
with	NULL
the	NULL
Rb	NULL
protein	NULL
in	NULL
late	NULL
E	NULL
differentiation	NULL
(	NULL
Figure	NULL
7a	NULL
)	NULL
.	NULL

No	NULL
PML/Rb	NULL
complex	NULL
was	NULL
detected	NULL
in	NULL
late	NULL
G	NULL
differentiation	NULL
(	NULL
Figure	NULL
7a	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
the	NULL
filters	NULL
were	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
the	NULL
reciprocal	NULL
antibody	NULL
,	NULL
confirming	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
PML	NULL
protein	NULL
in	NULL
anti-Rb	NULL
immunoprecipitates	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
PML	NULL
immunoprecipitate	NULL
was	NULL
blotted	NULL
together	NULL
with	NULL
a	NULL
control	NULL
anti-Rb	NULL
immunoprecipitate	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
probed	NULL
with	NULL
an	NULL
anti-Rb	NULL
polyclonal	NULL
Ab	NULL
(	NULL
Figure	NULL
7b	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

PML	NULL
immunoprecipitates	NULL
from	NULL
K562	NULL
cells	NULL
were	NULL
also	NULL
evaluated	NULL
.	NULL

This	NULL
experiment	NULL
showed	NULL
that	NULL
anti-PML	NULL
immunoprecipitates	NULL
contain	NULL
a	NULL
low	NULL
amount	NULL
of	NULL
a	NULL
105	NULL
kDa	NULL
pRb	NULL
,	NULL
confirming	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
PML/Rb	NULL
complex	NULL
in	NULL
HPCs	NULL
at	NULL
day	NULL
9	NULL
of	NULL
E	NULL
culture	NULL
(	NULL
Figure	NULL
7b	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
efficiency	NULL
of	NULL
PML	NULL
immunoprecipitation	NULL
was	NULL
verified	NULL
in	NULL
control	NULL
experiments	NULL
where	NULL
anti-PML	NULL
immunoprecipitates	NULL
were	NULL
blotted	NULL
and	NULL
probed	NULL
with	NULL
the	NULL
anti-PML	NULL
mAb	NULL
(	NULL
PG-M3	NULL
)	NULL
(	NULL
Figure	NULL
7b	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
PML/Rb	NULL
complex	NULL
was	NULL
controlled	NULL
by	NULL
co-immunoprecipitation/	NULL
Western	NULL
blot	NULL
experiments	NULL
with	NULL
PML	NULL
and	NULL
GATA-1	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

No	NULL
PML/GATA-1	NULL
complex	NULL
was	NULL
detected	NULL
at	NULL
day	NULL
9	NULL
of	NULL
E	NULL
culture	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Overall	NULL
these	NULL
findings	NULL
indicate	NULL
the	NULL
PML	NULL
protein	NULL
and	NULL
a	NULL
fraction	NULL
of	NULL
pRb1O05	NULL
specifically	NULL
interact	NULL
in	NULL
day	NULL
9	NULL
E	NULL
culture	NULL
.	NULL

Discussion	NULL
Hematopoiesis	NULL
is	NULL
a	NULL
multistep	NULL
proliferation	NULL
and	NULL
differ	NULL
entiation	NULL
process	NULL
,	NULL
which	NULL
is	NULL
sustained	NULL
by	NULL
a	NULL
pool	NULL
of	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
(	NULL
HSCs	NULL
)	NULL
.	NULL

HSCs	NULL
are	NULL
capable	NULL
of	NULL
corresponding	NULL
scrambled	NULL
oligomer	NULL
values	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Treatment	NULL
of	NULL
HPCs	NULL
grown	NULL
for	NULL
5	NULL
days	NULL
in	NULL
unilineage	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
(	NULL
top	NULL
)	NULL
or	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
(	NULL
bottom	NULL
)	NULL
culture	NULL
with	NULL
«	NULL
1-PML	NULL
or	NULL
scrambled	NULL
«	NULL
1-PML	NULL
oligomer	NULL
(	NULL
25	NULL
,	NULL
50	NULL
or	NULL
100	NULL
ug/ml	NULL
)	NULL
.	NULL

Mock	NULL
treated	NULL
controls	NULL
are	NULL
included	NULL
.	NULL

The	NULL
effect	NULL
on	NULL
BFU-E	NULL
and	NULL
CFU-G	NULL
colony	NULL
formation	NULL
in	NULL
semisolid	NULL
culture	NULL
induced	NULL
by	NULL
E-	NULL
or	NULL
G-specific	NULL
HGF	NULL
stimulus	NULL
is	NULL
shown	NULL
.	NULL

Mean	NULL
+s.e.m	NULL
.	NULL

values	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
presented	NULL
.	NULL

**P	NULL
<	NULL
0.01	NULL
when	NULL
compared	NULL
to	NULL
corresponding	NULL
scrambled	NULL
oligomer	NULL
values	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
Day	NULL
3	NULL
Day	NULL
5	NULL
Day	NULL
9	NULL
CONTROL	NULL
ANTI-SENSE	NULL
ser	NULL
a	NULL
1	NULL
-PML	NULL
ser	NULL
a	NULL
1-PML	NULL
Figure	NULL
5	NULL
(	NULL
a	NULL
)	NULL
Immunofluorescence	NULL
analysis	NULL
of	NULL
PML	NULL
expression	NULL
in	NULL
HPCs	NULL
differentiating	NULL
in	NULL
unilineage	NULL
E	NULL
liquid	NULL
culture	NULL
upon	NULL
treatment	NULL
with	NULL
an	NULL
optimal	NULL
concentration	NULL
(	NULL
100	NULL
ug/ml	NULL
!	NULL
)	NULL

of	NULL
antisense	NULL
oligomer	NULL
to	NULL
PML	NULL
(	NULL
«	NULL
1-PML	NULL
)	NULL
,	NULL
or	NULL
scrambled	NULL
«	NULL
1-PML	NULL
.	NULL

Oligomers	NULL
were	NULL
added	NULL
on	NULL
HPCs	NULL
at	NULL
day	NULL
0	NULL
of	NULL
culture	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
analysed	NULL
by	NULL
immunofluorescence	NULL
at	NULL
sequential	NULL
day	NULL
after	NULL
labeling	NULL
with	NULL
PG-M3	NULL
anti-PML	NULL
mAb	NULL
.	NULL

(	NULL
b	NULL
)	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
PML	NULL
expression	NULL
in	NULL
HPCs	NULL
differentiating	NULL
in	NULL
unilineage	NULL
E	NULL
liquid	NULL
culture	NULL
upon	NULL
treatment	NULL
with	NULL
an	NULL
optimal	NULL
concentration	NULL
(	NULL
100	NULL
ug/m	NULL
!	NULL
)	NULL

of	NULL
antisense	NULL
oligomer	NULL
to	NULL
PML	NULL
(	NULL
«	NULL
1-PML	NULL
)	NULL
,	NULL
or	NULL
scrambled	NULL
«	NULL
1-PML	NULL
(	NULL
Ser	NULL
«	NULL
1-PML	NULL
)	NULL
added	NULL
at	NULL
day	NULL
0	NULL
of	NULL
culture	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
for	NULL
RNA	NULL
extraction	NULL
at	NULL
day	NULL
7	NULL
and	NULL
day	NULL
9	NULL
from	NULL
the	NULL
culture	NULL
3535	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
3536	NULL
Tabel	NULL
2	NULL
Number	NULL
of	NULL
PML	NULL
PODs	NULL
in	NULL
erythroid	NULL
and	NULL
granulocytic	NULL
cultures	NULL
of	NULL
HPC	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
either	NULL
antisense	NULL
or	NULL
scrambled	NULL
PML	NULL
nucleotide	NULL
oligomers	NULL
Erythroid	NULL
cultures	NULL
Granulocytic	NULL
cultures	NULL
Treatment	NULL
day	NULL
3	NULL
day	NULL
5	NULL
day	NULL
9	NULL
day	NULL
3	NULL
day	NULL
5	NULL
day	NULL
9	NULL
None	NULL
(	NULL
control	NULL
)	NULL
9.6	NULL
+2.2	NULL
19.3+3.1	NULL
12.8	NULL
+2.6	NULL
9.8+1.7	NULL
8.1+1.2	NULL
5.2+1.3	NULL
Scrambled	NULL
10.4+3.1	NULL
18.1	NULL
+3.6	NULL
13.5+3.3	NULL
8.9+2.1	NULL
8.7+1.5	NULL
4.1	NULL
+1.6	NULL
Antisense	NULL
2.3+0.9	NULL
3.1	NULL
+1.8	NULL
3.7+1.9	NULL
2.1+0.6	NULL
1.6+0.6	NULL
0.3+0.1	NULL
Values	NULL
represent	NULL
the	NULL
mean	NULL
number	NULL
+s.d	NULL
.	NULL

of	NULL
PODs	NULL
evaluated	NULL
on	NULL
at	NULL
least	NULL
200	NULL
cells	NULL
120	NULL
7	NULL
100	NULL
2	NULL
5	NULL
8	NULL
89	NULL
R	NULL
6	NULL
£	NULL
i	NULL
60	NULL
'	NULL
C	NULL
a	NULL
8	NULL
P	NULL
ua	NULL
40	NULL
3	NULL
th	NULL
20	NULL
|	NULL
00	NULL
0	NULL
-	NULL
i	NULL
AS	NULL
(	NULL
a	NULL
)	NULL
Oligomer	NULL
0	NULL
0	NULL
0	NULL
0	NULL
0	NULL
25	NULL
50	NULL
25	NULL
50	NULL
0	NULL
0	NULL
12.5	NULL
25	NULL
12.5	NULL
25	NULL
125	NULL
25	NULL
Dosage	NULL
+	NULL
125	NULL
25	NULL
Ser	NULL
(	NULL
Sere	NULL
)	NULL
12.5	NULL
25	NULL
Oligomer	NULL
0	NULL
25	NULL
50	NULL
25	NULL
50	NULL
a	NULL
_	NULL
0	NULL
0	NULL
+	NULL
125	NULL
25	NULL
12.5	NULL
25	NULL
a	NULL
Dosage	NULL
125	NULL
25	NULL
Ser	NULL
c1-PML	NULL
o-Rb	NULL
o1-PML	NULL
1-PML	NULL
Ser	NULL
c1-PML	NULL
_	NULL
Ser	NULL
o-Rb	NULL
o.1-PML	NULL
o-Rb	NULL
4	NULL
+	NULL
+	NULL
+	NULL
Ser	NULL
o-Rb	NULL
Ser	NULL
«	NULL
1-PML	NULL
__	NULL
Scr	NULL
o-Rb	NULL
o-Rb	NULL
Figure	NULL
6	NULL
Effect	NULL
on	NULL
BFU-E	NULL
colony	NULL
formation	NULL
upon	NULL
HPCs	NULL
treatment	NULL
with	NULL
appropriate	NULL
concentrations	NULL
of	NULL
(	NULL
i	NULL
)	NULL
antisense	NULL
(	NULL
AS	NULL
)	NULL
oligomer	NULL
to	NULL
PML	NULL
(	NULL
«	NULL
1-PML	NULL
)	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
antisense	NULL
oligomer	NULL
to	NULL
Rb	NULL
(	NULL
«	NULL
-Rb	NULL
)	NULL
,	NULL
(	NULL
iii	NULL
)	NULL
scrambled	NULL
«	NULL
1-PML	NULL
(	NULL
Ser	NULL
«	NULL
1-PML	NULL
)	NULL
and/or	NULL
(	NULL
iv	NULL
)	NULL
scrambled	NULL
a-Rb	NULL
(	NULL
Ser	NULL
a-Rb	NULL
)	NULL
,	NULL
added	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
as	NULL
indicated	NULL
at	NULL
day	NULL
5	NULL
of	NULL
culture	NULL
.	NULL

Total	NULL
oligomer	NULL
dosage	NULL
is	NULL
indicated	NULL
(	NULL
ug/m1	NULL
)	NULL
:	NULL
combined	NULL
treatment	NULL
involved	NULL
equal	NULL
amounts	NULL
of	NULL
the	NULL
two	NULL
oligomers	NULL
.	NULL

**P	NULL
<	NULL
0.01	NULL
when	NULL
compared	NULL
with	NULL
control	NULL
groups	NULL
treated	NULL
with	NULL
the	NULL
same	NULL
dosage	NULL
of	NULL
scrambled	NULL
oligomers	NULL
(	NULL
Ser	NULL
«	NULL
1-PML	NULL
+Scr	NULL
«	NULL
-Rb	NULL
;	NULL
Ser	NULL
a-Rb+	NULL
«	NULL
1-PML	NULL
;	NULL
Ser	NULL
«	NULL
1-PML	NULL
+a-Rb	NULL
)	NULL
.	NULL

°°P	NULL
<	NULL
0.01	NULL
when	NULL
compared	NULL
with	NULL
all	NULL
other	NULL
groups	NULL
treated	NULL
with	NULL
50	NULL
ug	NULL
total	NULL
oligomer	NULL
dosage	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
when	NULL
compared	NULL
with	NULL
control	NULL
scrambled	NULL
«	NULL
1-PML	NULL
(	NULL
Ser	NULL
«	NULL
1-PML	NULL
)	NULL
group	NULL
.	NULL

When	NULL
a	NULL
combination	NULL
of	NULL
two	NULL
oligomers	NULL
was	NULL
used	NULL
,	NULL
half	NULL
dose	NULL
of	NULL
each	NULL
oligomer	NULL
was	NULL
added	NULL
(	NULL
i.e	NULL
.	NULL

column	NULL
15	NULL
;	NULL
total	NULL
dose	NULL
50	NULL
ug/ml	NULL
:	NULL
25	NULL
ug/	NULL
ml	NULL
«	NULL
1-PML	NULL
+25	NULL
ug/ml	NULL
Ser	NULL
a-Rb	NULL
)	NULL
extensive	NULL
self-renewal	NULL
and	NULL
feed	NULL
into	NULL
lineage-committed	NULL
HPCs	NULL
.	NULL

We	NULL
have	NULL
developed	NULL
methodology	NULL
for	NULL
normal	NULL
HPC/HSC	NULL
purification	NULL
(	NULL
Gabbianelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
unilineage	NULL
differentiation	NULL
,	NULL
maturation	NULL
in	NULL
liquid-phase	NULL
suspension	NULL
culture	NULL
:	NULL
this	NULL
allows	NULL
a	NULL
step-by-step	NULL
analysis	NULL
of	NULL
hematopoietic	NULL
differentiation/maturation	NULL
through	NULL
a	NULL
single	NULL
lineage	NULL
at	NULL
both	NULL
cellular	NULL
and	NULL
molecular	NULL
levels	NULL
(	NULL
Labbaye	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994	NULL
,	NULL
1995	NULL
;	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

We	NULL
have	NULL
exploited	NULL
this	NULL
model	NULL
system	NULL
to	NULL
investigate	NULL
the	NULL
pattern	NULL
of	NULL
expression	NULL
and	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
in	NULL
hematopoietic	NULL
differentiation	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
,	NULL
1995	NULL
;	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
relevance	NULL
of	NULL
PML	NULL
in	NULL
the	NULL
physiology	NULL
of	NULL
the	NULL
hematopoietic	NULL
system	NULL
is	NULL
indirectly	NULL
suggested	NULL
by	NULL
its	NULL
involvement	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
APL	NULL
as	NULL
a	NULL
partner	NULL
of	NULL
RAR	NULL
«	NULL
in	NULL
the	NULL
PML/RAR	NULL
«	NULL
fusion	NULL
protein	NULL
(	NULL
Warrell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Grignani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
de	NULL
The	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
is	NULL
also	NULL
directly	NULL
supported	NULL
by	NULL
the	NULL
phenotypic	NULL
analysis	NULL
of	NULL
PML	NULL
--	NULL
mice	NULL
(	NULL
Wang	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

This	NULL
rearrangement	NULL
is	NULL
much	NULL
more	NULL
frequently	NULL
observed	NULL
as	NULL
compared	NULL
with	NULL
other	NULL
known	NULL
APL	NULL
fusion-proteins	NULL
,	NULL
PLZF/RAR	NULL
«	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
NPM/	NULL
RAR	NULL
«	NULL
(	NULL
Redner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
NuMA-RARa	NULL
(	NULL
Wells	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
reported	NULL
in	NULL
M3	NULL
leukemias	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
PML	NULL
possesses	NULL
structural	NULL
and	NULL
functional	NULL
features	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
(	NULL
Kastner	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Guiochon-Mantel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
and	NULL
biological	NULL
activity	NULL
of	NULL
a	NULL
growth	NULL
regulator	NULL
(	NULL
Mu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

PML	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
is	NULL
low	NULL
in	NULL
quiescent	NULL
HPCs	NULL
and	NULL
is	NULL
induced	NULL
by	NULL
growth	NULL
factor	NULL
stimulation	NULL
of	NULL
E	NULL
G	NULL
A	NULL
ou	NULL
D	NULL
a9d11d49	NULL
2	NULL
3	NULL
plosrko	NULL
-	NULL
wa	NULL
MHB	NULL
-	NULL
-	NULL
mm	NULL
B	NULL
E	NULL
eo-	NULL
{	NULL
4	NULL
mw	NULL
-	NULL
da9d11	NULL
2	NULL
IP	NULL
:	NULL
97	NULL
--	NULL
wan	NULL
w	NULL
PML	NULL
66	NULL
-	NULL
_/	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
boe	NULL
a	NULL
~~~	NULL
3	NULL
O	NULL
MW	NULL
d9	NULL
d11	NULL
ag	NULL
2	NULL
$	NULL
97	NULL
-	NULL
_	NULL
ws	NULL
wa	NULL
wa	NULL
|	NULL
PML	NULL
6p	NULL
-	NULL
|®	NULL
3	NULL
4	NULL
3	NULL
aq	NULL
K562	NULL
Rb	NULL
Rb	NULL
PML	NULL
Rb	NULL
PML	NULL
Rb	NULL
-	NULL
p105	NULL
Rb	NULL
Figure	NULL
7	NULL
-	NULL
(	NULL
a	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
immunoprecipitated	NULL
with	NULL
anti-pRb105	NULL
mAb	NULL
X55	NULL
from	NULL
:	NULL
4x	NULL
10°	NULL
day	NULL
9	NULL
or	NULL
day	NULL
11	NULL
E	NULL
,	NULL
day	NULL
9	NULL
G	NULL
cells	NULL
and	NULL
from	NULL
2x	NULL
10°	NULL
K562	NULL
or	NULL
SAOS-2	NULL
cells	NULL
.	NULL

The	NULL
immunoprecipitated	NULL
materials	NULL
were	NULL
analysed	NULL
by	NULL
8	NULL
%	NULL
SDS-PAGE	NULL
.	NULL

After	NULL
blotting	NULL
,	NULL
(	NULL
i	NULL
)	NULL
the	NULL
membrane	NULL
was	NULL
first	NULL
treated	NULL
with	NULL
a	NULL
polyclonal	NULL
anti-pRb105	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
;	NULL
as	NULL
expected	NULL
,	NULL
pRb	NULL
is	NULL
not	NULL
detectable	NULL
in	NULL
SAOS-2	NULL
extracts	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
same	NULL
membrane	NULL
was	NULL
then	NULL
treated	NULL
,	NULL
after	NULL
stripping	NULL
,	NULL
with	NULL
anti-PML	NULL
mAb	NULL
PG-M3	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
immunoprecipitated	NULL
with	NULL
anti-PML	NULL
mAb	NULL
,	NULL
PG-M3	NULL
or	NULL
with	NULL
anti-pRb105	NULL
mAb	NULL
,	NULL
XZ55	NULL
,	NULL
from	NULL
4	NULL
x	NULL
10°	NULL
day	NULL
9	NULL
E	NULL
cells	NULL
.	NULL

The	NULL
immunoprecipitated	NULL
materials	NULL
were	NULL
analysed	NULL
by	NULL
8	NULL
%	NULL
SDS-PAGE	NULL
.	NULL

After	NULL
blotting	NULL
,	NULL
(	NULL
i	NULL
)	NULL
one	NULL
membrane	NULL
was	NULL
treated	NULL
with	NULL
anti-PML	NULL
mAb	NULL
,	NULL
PG-M3	NULL
,	NULL
showing	NULL
two	NULL
major	NULL
bands	NULL
corresponding	NULL
to	NULL
the	NULL
different	NULL
isoforms	NULL
(	NULL
de	NULL
The	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
at	NULL
approximately	NULL
90	NULL
and	NULL
70	NULL
KDa	NULL
,	NULL
respectively	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
a	NULL
second	NULL
membrane	NULL
was	NULL
treated	NULL
with	NULL
anti-pRb105	NULL
polyclonal	NULL
Ab	NULL
,	NULL
SC-15	NULL
,	NULL
showing	NULL
the	NULL
pRb105	NULL
band	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
both	NULL
E	NULL
and	NULL
G	NULL
differentiation	NULL
.	NULL

Subsequently	NULL
,	NULL
during	NULL
precursor	NULL
maturation	NULL
,	NULL
PML	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
is	NULL
maintained	NULL
in	NULL
the	NULL
E	NULL
series	NULL
,	NULL
but	NULL
is	NULL
down	NULL
modulated	NULL
in	NULL
the	NULL
G	NULL
pathway	NULL
.	NULL

Notably	NULL
,	NULL
in	NULL
another	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
PML	NULL
is	NULL
expressed	NULL
during	NULL
megakaryocytic	NULL
differentiation	NULL
(	NULL
un-published	NULL
results	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
is	NULL
specifically	NULL
suppressed	NULL
during	NULL
late	NULL
G	NULL
maturation	NULL
.	NULL

The	NULL
antisense	NULL
oligomer	NULL
approach	NULL
allowed	NULL
an	NULL
insight	NULL
into	NULL
the	NULL
possible	NULL
functional	NULL
role	NULL
of	NULL
PML	NULL
in	NULL
the	NULL
normal	NULL
hematopoietic	NULL
differentiation	NULL
process	NULL
.	NULL

Suppression	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
in	NULL
early	NULL
HPCs	NULL
(	NULL
day	NULL
0	NULL
of	NULL
culture	NULL
)	NULL
markedly	NULL
inhibits	NULL
both	NULL
BFU-E	NULL
and	NULL
CFU-G	NULL
colony	NULL
formation	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
the	NULL
PML	NULL
protein	NULL
is	NULL
required	NULL
in	NULL
early	NULL
normal	NULL
hematopoiesis	NULL
,	NULL
possibly	NULL
playing	NULL
a	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
HPC	NULL
cell	NULL
cycling	NULL
.	NULL

Subsequently	NULL
,	NULL
in	NULL
more	NULL
advanced	NULL
HPCs	NULL
(	NULL
day	NULL
5	NULL
of	NULL
culture	NULL
)	NULL
,	NULL
suppression	NULL
of	NULL
PML	NULL
expression	NULL
induces	NULL
a	NULL
dose	NULL
dependent	NULL
inhibition	NULL
of	NULL
late	NULL
BFU-E	NULL
,	NULL
but	NULL
not	NULL
CFU-G	NULL
,	NULL
colony	NULL
formation	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
PML	NULL
protein	NULL
is	NULL
required	NULL
for	NULL
erythroid	NULL
maturation	NULL
,	NULL
but	NULL
is	NULL
dispensable	NULL
for	NULL
late	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

These	NULL
data	NULL
are	NULL
also	NULL
relevant	NULL
for	NULL
the	NULL
understanding	NULL
of	NULL
the	NULL
biological	NULL
function	NULL
of	NULL
the	NULL
normal	NULL
PML	NULL
protein	NULL
.	NULL

PML	NULL
is	NULL
required	NULL
for	NULL
both	NULL
early	NULL
hematopoiesis	NULL
and	NULL
E	NULL
colony	NULL
development	NULL
,	NULL
and	NULL
thus	NULL
can	NULL
not	NULL
be	NULL
regarded	NULL
simply	NULL
as	NULL
a	NULL
growth	NULL
controller	NULL
,	NULL
but	NULL
must	NULL
also	NULL
have	NULL
a	NULL
tissue-specific	NULL
function	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
cycle	NULL
and	NULL
differentiation	NULL
,	NULL
possibly	NULL
through	NULL
interaction	NULL
with	NULL
tissue-specific	NULL
nuclear	NULL
proteins	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
PML	NULL
expression	NULL
during	NULL
HPC	NULL
differentiation	NULL
and	NULL
precursor	NULL
maturation	NULL
,	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
described	NULL
for	NULL
another	NULL
nuclear	NULL
phospho-protein	NULL
,	NULL
pRb105	NULL
,	NULL
known	NULL
as	NULL
a	NULL
tumor	NULL
suppressor	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

pRb	NULL
is	NULL
a	NULL
master	NULL
regulator	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
differentiation	NULL
(	NULL
Chen	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996a	NULL
,	NULL
b	NULL
and	NULL
for	NULL
review	NULL
see	NULL
Taya	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
functions	NULL
of	NULL
Rb	NULL
depend	NULL
on	NULL
its	NULL
association	NULL
with	NULL
other	NULL
proteins	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
several	NULL
groups	NULL
have	NULL
recently	NULL
documented	NULL
the	NULL
apparent	NULL
role	NULL
of	NULL
pRb	NULL
in	NULL
terminal	NULL
cell	NULL
differentiation	NULL
through	NULL
its	NULL
capacity	NULL
to	NULL
directly	NULL
interact	NULL
with	NULL
and	NULL
activate	NULL
specific	NULL
TFs	NULL
,	NULL
such	NULL
as	NULL
NF-IL6	NULL
in	NULL
monocyte/macrophage	NULL
precursors	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996b	NULL
)	NULL
or	NULL
other	NULL
members	NULL
of	NULL
the	NULL
CAAT/enhancer-binding	NULL
protein	NULL
(	NULL
C/EBP	NULL
)	NULL
family	NULL
in	NULL
adipocyte	NULL
culture	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996a	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
experiments	NULL
,	NULL
separate	NULL
addition	NULL
of	NULL
suboptimal	NULL
concentrations	NULL
of	NULL
«	NULL
-Rb	NULL
and	NULL
«	NULL
l-PML	NULL
oligomers	NULL
slightly	NULL
inhibited	NULL
day	NULL
0	NULL
HPC	NULL
differentia-	NULL
3537	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
3538	NULL
tion	NULL
.	NULL

Simultaneous	NULL
oligomer	NULL
addition	NULL
-	NULL
completely	NULL
blocked	NULL
E	NULL
,	NULL
but	NULL
not	NULL
G	NULL
maturation	NULL
,	NULL
in	NULL
day	NULL
5	NULL
E	NULL
and	NULL
G	NULL
cultures	NULL
.	NULL

This	NULL
effect	NULL
seems	NULL
to	NULL
be	NULL
synergistic	NULL
,	NULL
suggesting	NULL
that	NULL
PML	NULL
and	NULL
Rb	NULL
cooperate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
erythropoiesis	NULL
.	NULL

The	NULL
functional	NULL
interaction	NULL
between	NULL
PML	NULL
and	NULL
Rb	NULL
may	NULL
consist	NULL
in	NULL
a	NULL
coordinate	NULL
activity	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
on	NULL
the	NULL
same	NULL
molecular	NULL
pathways	NULL
.	NULL

However	NULL
,	NULL
pRb105	NULL
co-immunoprecipitates	NULL
with	NULL
the	NULL
PML	NULL
protein	NULL
from	NULL
erythroid	NULL
precursors	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
biological	NULL
effect	NULL
of	NULL
the	NULL
functional	NULL
PML	NULL
and	NULL
Rb	NULL
knock-out	NULL
may	NULL
derive	NULL
from	NULL
the	NULL
decrease	NULL
of	NULL
a	NULL
proteic	NULL
complex	NULL
containing	NULL
both	NULL
PML	NULL
and	NULL
Rb	NULL
.	NULL

Indeed	NULL
,	NULL
using	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
have	NULL
recently	NULL
demonstrated	NULL
and	NULL
mapped	NULL
the	NULL
physical	NULL
PML/Rb	NULL
interaction	NULL
within	NULL
PML-NBs	NULL
:	NULL
interestingly	NULL
,	NULL
PML	NULL
can	NULL
modulate	NULL
RB	NULL
activity	NULL
on	NULL
the	NULL
glycocorticoid	NULL
receptor	NULL
gene	NULL
promoter	NULL
(	NULL
Alcalay	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
co-immunoprecipitation	NULL
experiments	NULL
shown	NULL
here	NULL
were	NULL
performed	NULL
in	NULL
normal	NULL
cells	NULL
and	NULL
did	NULL
not	NULL
involve	NULL
overexpression	NULL
of	NULL
the	NULL
interacting	NULL
proteins	NULL
,	NULL
supporting	NULL
the	NULL
notion	NULL
of	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
physiological	NULL
PML/Rb	NULL
complex	NULL
in	NULL
normal	NULL
cells	NULL
.	NULL

We	NULL
observed	NULL
PML/Rb	NULL
coimmunoprecipitation	NULL
only	NULL
after	NULL
a	NULL
long	NULL
exposure	NULL
of	NULL
the	NULL
membranes	NULL
.	NULL

This	NULL
finding	NULL
indicates	NULL
that	NULL
the	NULL
amount	NULL
of	NULL
PML-Rb	NULL
complex	NULL
in	NULL
erythroblasts	NULL
accounts	NULL
for	NULL
a	NULL
small	NULL
proportion	NULL
of	NULL
the	NULL
total	NULL
pRb	NULL
protein	NULL
,	NULL
which	NULL
may	NULL
localize	NULL
within	NULL
the	NULL
PML	NULL
NBs	NULL
(	NULL
Alcalay	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
function	NULL
of	NULL
the	NULL
interacting	NULL
subfractions	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
is	NULL
presently	NULL
unknown	NULL
,	NULL
but	NULL
it	NULL
may	NULL
consist	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
specific	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
PML	NULL
and	NULL
Rb	NULL
are	NULL
required	NULL
for	NULL
erythroid	NULL
differentiation	NULL
,	NULL
and	NULL
that	NULL
the	NULL
two	NULL
proteins	NULL
physically	NULL
interact	NULL
in	NULL
maturing	NULL
erythroid	NULL
cells	NULL
,	NULL
provides	NULL
the	NULL
first	NULL
evidence	NULL
for	NULL
a	NULL
functional	NULL
role	NULL
of	NULL
the	NULL
PML/Rb	NULL
complex	NULL
,	NULL
specifically	NULL
in	NULL
normal	NULL
hematopoiesis	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Hematopoietic	NULL
growth	NULL
factors	NULL
and	NULL
cell	NULL
culture	NULL
Recombinant	NULL
human	NULL
growth	NULL
factors	NULL
were	NULL
obtained	NULL
from	NULL
standard	NULL
commercial	NULL
sources	NULL
(	NULL
Gabbianelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
,	NULL
1995	NULL
;	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Iscove	NULL
's	NULL
medium	NULL
(	NULL
IMDM	NULL
,	NULL
GIBCO	NULL
)	NULL
was	NULL
freshly	NULL
prepared	NULL
weekly	NULL
.	NULL

Cell	NULL
lines	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
Western	NULL
blotting	NULL
and	NULL
immunoprecipitation	NULL
experiments	NULL
(	NULL
K562	NULL
,	NULL
Jurkat	NULL
,	NULL
SAOS-2	NULL
,	NULL
U937-PML3	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
.	NULL

Adult	NULL
peripheral	NULL
blood	NULL
(	NULL
PB	NULL
)	NULL
HPC	NULL
purification	NULL
and	NULL
clonogenetic	NULL
assay	NULL
HPCs	NULL
were	NULL
purified	NULL
from	NULL
the	NULL
PB	NULL
buffy	NULL
coat	NULL
according	NULL
to	NULL
the	NULL
method	NULL
previously	NULL
reported	NULL
(	NULL
Gabbianelli	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
and	NULL
subsequently	NULL
modified	NULL
as	NULL
described	NULL
(	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Purified	NULL
HPC	NULL
clonogenetic	NULL
cultures	NULL
FCS~-	NULL
were	NULL
supplemented	NULL
with	NULL
IL-3	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
,	NULL
GM-CSF	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
presence	NULL
or	NULL
not	NULL
of	NULL
Epo	NULL
(	NULL
3	NULL
U	NULL
)	NULL
in	NULL
order	NULL
to	NULL
obtain	NULL
CFU-GM	NULL
colonies	NULL
or	NULL
BFU-E	NULL
plus	NULL
CFU-GM	NULL
colonies	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

HPC	NULL
erythroid	NULL
(	NULL
E	NULL
)	NULL
and	NULL
granulopoietic	NULL
(	NULL
G	NULL
)	NULL
liquid	NULL
suspension	NULL
culture	NULL
Step	NULL
IIIP	NULL
HPCs	NULL
were	NULL
seeded	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
)	NULL
and	NULL
grown	NULL
in	NULL
liquid	NULL
FCS~-	NULL
medium	NULL
(	NULL
Valtieri	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
supplemented	NULL
in	NULL
E	NULL
culture	NULL
with	NULL
low	NULL
doses	NULL
of	NULL
IL-3	NULL
(	NULL
0.01	NULL
U/ml	NULL
!	NULL
)	NULL

and	NULL
GM-CSF	NULL
(	NULL
0.001	NULL
ng	NULL
)	NULL
and	NULL
a	NULL
saturating	NULL
level	NULL
of	NULL
Epo	NULL
(	NULL
3	NULL
U	NULL
)	NULL
and	NULL
in	NULL
G	NULL
culture	NULL
with	NULL
low	NULL
amounts	NULL
of	NULL
IL-3	NULL
(	NULL
1	NULL
U	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
0.1	NULL
ng	NULL
)	NULL
and	NULL
a	NULL
saturating	NULL
amount	NULL
of	NULL
G-CSF	NULL
(	NULL
10	NULL
ng	NULL
)	NULL
as	NULL
described	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
fully	NULL
humidified	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
/5	NULL
%	NULL
0	NULL
,	NULL
/90	NULL
%	NULL
N	NULL
,	NULL
and	NULL
were	NULL
periodically	NULL
counted	NULL
and	NULL
analysed	NULL
for	NULL
morphology	NULL
,	NULL
membrane	NULL
phenotype	NULL
,	NULL
and	NULL
PML	NULL
gene	NULL
expression	NULL
.	NULL

Cell	NULL
surface	NULL
marker	NULL
and	NULL
morphology	NULL
analysis	NULL
To	NULL
evaluate	NULL
the	NULL
differentiation	NULL
of	NULL
HPCs	NULL
differentiating	NULL
along	NULL
the	NULL
E	NULL
and	NULL
G	NULL
lineages	NULL
the	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
the	NULL
following	NULL
monoclonal	NULL
antibodies	NULL
labeled	NULL
either	NULL
with	NULL
FITC	NULL
or	NULL
PE	NULL
:	NULL
anti-CD34	NULL
,	NULL
anti-CD15	NULL
,	NULL
anti-CDlla	NULL
and	NULL
anti-Glycophorin	NULL
A	NULL
(	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Fluorescent	NULL
cells	NULL
were	NULL
analysed	NULL
with	NULL
a	NULL
flow	NULL
cytometer	NULL
(	NULL
FACS	NULL
Scan	NULL
,	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

For	NULL
cell	NULL
morphology	NULL
analysis	NULL
cytospin	NULL
preparations	NULL
of	NULL
cells	NULL
were	NULL
performed	NULL
at	NULL
different	NULL
days	NULL
of	NULL
culture	NULL
and	NULL
stained	NULL
with	NULL
May-Griinwald-Giemsa	NULL
.	NULL

At	NULL
least	NULL
200	NULL
cells	NULL
were	NULL
examined	NULL
and	NULL
classified	NULL
according	NULL
to	NULL
their	NULL
differentiation/maturation	NULL
stage	NULL
.	NULL

Morphology	NULL
and	NULL
immunofluorescence	NULL
analysis	NULL
Cells	NULL
were	NULL
harvested	NULL
on	NULL
different	NULL
days	NULL
,	NULL
smeared	NULL
on	NULL
glass	NULL
slides	NULL
by	NULL
cytospin	NULL
centrifugation	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
May-Griinwald-Giemsa	NULL
.	NULL

The	NULL
anti-PML	NULL
mAb	NULL
PG-M3	NULL
(	NULL
Flenghi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
was	NULL
used	NULL
for	NULL
immunofluorescence	NULL
labeling	NULL
of	NULL
PML	NULL
.	NULL

Indirect	NULL
immunofluorescence	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Grignani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
examined	NULL
under	NULL
a	NULL
fluorescence	NULL
microscope	NULL
(	NULL
Microphot	NULL
,	NULL
Nikon	NULL
)	NULL
equipped	NULL
with	NULL
a	NULL
highly	NULL
sensitive	NULL
videocamera	NULL
and	NULL
a	NULL
system	NULL
for	NULL
digital	NULL
images	NULL
acquisition	NULL
.	NULL

Reverse	NULL
transcriptase	NULL
(	NULL
RT-PCR	NULL
)	NULL
mRNA	NULL
analysis	NULL
The	NULL
method	NULL
for	NULL
semiquantitative	NULL
RT-PCR	NULL
analysis	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
,	NULL
1995	NULL
,	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

cDNAs	NULL
were	NULL
normalized	NULL
by	NULL
the	NULL
B2-microglobulin	NULL
gene	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

K562	NULL
cell	NULL
line	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
positive	NULL
control	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
RT-RNA	NULL
(	NULL
20	NULL
ng	NULL
)	NULL
from	NULL
each	NULL
sample	NULL
and	NULL
a	NULL
mock	NULL
reaction	NULL
(	NULL
negative	NULL
controls	NULL
)	NULL
were	NULL
amplified	NULL
to	NULL
exclude	NULL
the	NULL
presence	NULL
of	NULL
contaminant	NULL
DNA	NULL
.	NULL

PML	NULL
primers	NULL
and	NULL
probe	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
PML-sense	NULL
5-	NULL
(	NULL
TTC	NULL
GGA	NULL
GGA	NULL
GGA	NULL
GTT	NULL
CCA	NULL
)	NULL
-3	NULL
(	NULL
from	NULL
219-237	NULL
)	NULL
;	NULL
a-sense	NULL
PML	NULL
:	NULL
5-	NULL
(	NULL
GTG	NULL
TGC	NULL
CTC	NULL
GAA	NULL
GCA	NULL
CTT	NULL
)	NULL
-3	NULL
'	NULL
(	NULL
from	NULL
527-545	NULL
)	NULL
;	NULL
internal	NULL
probe	NULL
:	NULL
5-	NULL
(	NULL
CTAGGTGCAGACACACCC-GCCCT	NULL
)	NULL
-3	NULL
'	NULL
(	NULL
from	NULL
368-391	NULL
)	NULL
(	NULL
de	NULL
Thé	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
amplification	NULL
procedure	NULL
included	NULL
denaturation	NULL
at	NULL
95°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
annealing	NULL
at	NULL
56°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
45	NULL
s	NULL
during	NULL
30	NULL
PCR	NULL
cycles	NULL
,	NULL
ie	NULL
.	NULL

,	NULL
within	NULL
the	NULL
range	NULL
of	NULL
linear	NULL
amplification	NULL
this	NULL
cycle	NULL
number	NULL
allowed	NULL
a	NULL
linear	NULL
cDNA	NULL
dose	NULL
response	NULL
.	NULL

In	NULL
control	NULL
experiments	NULL
,	NULL
serial	NULL
dilutions	NULL
of	NULL
samples	NULL
were	NULL
amplified	NULL
;	NULL
the	NULL
dose-response	NULL
curves	NULL
showed	NULL
linearity	NULL
for	NULL
all	NULL
points	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Relative	NULL
intensities	NULL
of	NULL
bands	NULL
were	NULL
quantified	NULL
by	NULL
scanning	NULL
with	NULL
a	NULL
laser	NULL
densitometer	NULL
(	NULL
Phosphor-imager	NULL
Molecular	NULL
Dynamics	NULL
Inc.	NULL
;	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Protein	NULL
extraction	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
Proteins	NULL
were	NULL
extracted	NULL
from	NULL
HPCs	NULL
(	NULL
4	NULL
x	NULL
10°	NULL
)	NULL
collected	NULL
at	NULL
day	NULL
9	NULL
and	NULL
12	NULL
from	NULL
E	NULL
and	NULL
G	NULL
cultures	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
and	NULL
analysed	NULL
by	NULL
Western	NULL
blot	NULL
as	NULL
described	NULL
in	NULL
Grignani	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
normalized	NULL
for	NULL
cell	NULL
number	NULL
and	NULL
loaded	NULL
onto	NULL
8	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
.	NULL

K562	NULL
cell	NULL
line	NULL
and	NULL
U937-PML3	NULL
(	NULL
U937	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
PML3	NULL
cDNA	NULL
(	NULL
Flenghi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
)	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
controls	NULL
.	NULL

The	NULL
anti-PML	NULL
mAb	NULL
PG-M3	NULL
(	NULL
Flenghi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
was	NULL
used	NULL
to	NULL
probe	NULL
the	NULL
blotted	NULL
membrane	NULL
for	NULL
PML	NULL
.	NULL

Bands	NULL
were	NULL
visualized	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

HPC	NULL
oligomer	NULL
treatment	NULL
and	NULL
clonogenetic	NULL
assay	NULL
Oligomer	NULL
treatment	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

We	NULL
have	NULL
used	NULL
two	NULL
sets	NULL
of	NULL
phosphorothioate	NULL
oligodeoxynucleotides	NULL
in	NULL
our	NULL
experiments	NULL
.	NULL

Oligomers	NULL
-	NULL
The	NULL
following	NULL
phosphorothioate	NULL
oligodeoxynucleotides	NULL
were	NULL
used	NULL
:	NULL
(	NULL
i	NULL
)	NULL
the	NULL
first	NULL
set	NULL
was	NULL
,	NULL
antisense	NULL
PML	NULL
(	NULL
«	NULL
l-PML	NULL
)	NULL
:	NULL
5-	NULL
(	NULL
CAT	NULL
TGC	NULL
TGG	NULL
CAG	NULL
CGC	NULL
AGA	NULL
)	NULL
3	NULL
,	NULL
complementary	NULL
to	NULL
nucleotides	NULL
starting	NULL
from	NULL
241-259	NULL
PML	NULL
mRNA	NULL
coding	NULL
sequence	NULL
(	NULL
de	NULL
The	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
;	NULL
scrambled	NULL
«	NULL
1-PML	NULL
(	NULL
Ser	NULL
«	NULL
1-PML	NULL
)	NULL
,	NULL
5-	NULL
(	NULL
GGC	NULL
ACG	NULL
CCA	NULL
TGC	NULL
AGT	NULL
AGT	NULL
)	NULL
-3	NULL
'	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
second	NULL
set	NULL
was	NULL
,	NULL
antisense	NULL
PML	NULL
(	NULL
«	NULL
2-PML	NULL
)	NULL
:	NULL
5-	NULL
(	NULL
CAGACAAGGCAGCAGCTT	NULL
)	NULL
-3	NULL
'	NULL
,	NULL
complementary	NULL
to	NULL
nucleotides	NULL
starting	NULL
from	NULL
283-301	NULL
PML	NULL
mRNA	NULL
coding	NULL
sequence	NULL
(	NULL
de	NULL
Thé	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
;	NULL
scrambled	NULL
«	NULL
2-PML	NULL
(	NULL
Ser	NULL
«	NULL
2-PML	NULL
)	NULL
,	NULL
5-	NULL
(	NULL
AACTGAGATCAAGGC-CGC	NULL
)	NULL
-3	NULL
'	NULL
,	NULL
(	NULL
iii	NULL
)	NULL
antisense	NULL
Rb	NULL
(	NULL
«	NULL
-Rb	NULL
)	NULL
,	NULL
5-	NULL
(	NULL
GTGAACGA-CATCTCATCTAGG	NULL
)	NULL
-3	NULL
'	NULL
-	NULL
(	NULL
Condorelli	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
scrambled	NULL
«	NULL
-Rb	NULL
(	NULL
Scr	NULL
«	NULL
-Rb	NULL
)	NULL
,	NULL
5-	NULL
(	NULL
TACTGGCTAAGCC-TAGCATGA	NULL
)	NULL
-3	NULL
'	NULL
.	NULL

Oligomer	NULL
treatment	NULL
Step	NULL
IIIP	NULL
cells	NULL
were	NULL
diluted	NULL
in	NULL
FCS-medium	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
)	NULL
supplemented	NULL
with	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
for	NULL
unilineage	NULL
E	NULL
or	NULL
G	NULL
differentiation	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
antisense	NULL
or	NULL
randomly	NULL
scrambled	NULL
phosphorothioate	NULL
oligomers	NULL
at	NULL
appropriate	NULL
concentrations	NULL
(	NULL
25	NULL
,	NULL
50	NULL
and	NULL
100	NULL
ug/ml	NULL
)	NULL
added	NULL
either	NULL
at	NULL
day	NULL
0	NULL
or	NULL
at	NULL
day	NULL
5	NULL
and	NULL
incubated	NULL
overnight	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
plated	NULL
in	NULL
clonogenetic	NULL
culture	NULL
in	NULL
triplicate	NULL
dishes	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
Labbaye	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Valtieri	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Caré	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Fluoresceinated	NULL
oligomer	NULL
uptake	NULL
was	NULL
evaluated	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
Giampaolo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
anti-PML	NULL
mAb	NULL
PG-M3	NULL
(	NULL
Flenghi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
was	NULL
used	NULL
for	NULL
immunofluorescence	NULL
labeling	NULL
of	NULL
PML	NULL
in	NULL
E	NULL
culture	NULL
References	NULL
Ahn	NULL
JH	NULL
and	NULL
Hayward	NULL
GS	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
71	NULL
,	NULL
4599-4613	NULL
.	NULL

Ahn	NULL
JH	NULL
,	NULL
Brignale	NULL
III	NULL
EJ	NULL
and	NULL
Hayward	NULL
GS	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
18	NULL
,	NULL
4899-4913	NULL
.	NULL

Alcalay	NULL
M	NULL
,	NULL
Tomassoni	NULL
L	NULL
,	NULL
Colombo	NULL
E	NULL
,	NULL
Stoldt	NULL
S	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Helin	NULL
K	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
18	NULL
,	NULL
1084-1093	NULL
.	NULL

Alcalay	NULL
M	NULL
,	NULL
Zangrilli	NULL
D	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
4840-4844	NULL
.	NULL

Borden	NULL
KL	NULL
,	NULL
Boddy	NULL
MN	NULL
,	NULL
Lally	NULL
J	NULL
,	NULL
O'Reilly	NULL
NJ	NULL
,	NULL
Martin	NULL
S	NULL
,	NULL
Howe	NULL
K	NULL
,	NULL
Solomon	NULL
E	NULL
and	NULL
Freemont	NULL
PS	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
1532-1541	NULL
.	NULL

Borden	NULL
KL	NULL
,	NULL
Lally	NULL
JM	NULL
,	NULL
Martin	NULL
SR	NULL
,	NULL
O'Reilly	NULL
NJ	NULL
,	NULL
Solomon	NULL
E	NULL
and	NULL
Freemont	NULL
PS	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
1601-1606	NULL
.	NULL

Brown	NULL
D	NULL
,	NULL
Kogan	NULL
S	NULL
,	NULL
Lagasse	NULL
E	NULL
,	NULL
Weissman	NULL
I	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Atwater	NULL
S	NULL
and	NULL
Bishop	NULL
JM	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
2551-2556	NULL
.	NULL

Caré	NULL
A	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Bassani	NULL
A	NULL
,	NULL
Tritarelli	NULL
E	NULL
,	NULL
Montesoro	NULL
E	NULL
,	NULL
Samoggia	NULL
P	NULL
,	NULL
Cianetti	NULL
L	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
4872-4877	NULL
.	NULL

Castaigne	NULL
S	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Berger	NULL
R	NULL
,	NULL
Fenaux	NULL
P	NULL
and	NULL
Degos	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
76	NULL
,	NULL
1704-1709	NULL
.	NULL

Chang	NULL
KS	NULL
,	NULL
Fan	NULL
YH	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Liu	NULL
J	NULL
and	NULL
Mu	NULL
ZM	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
,	NULL
3646-3653	NULL
.	NULL

Chen	NULL
PL	NULL
,	NULL
Riley	NULL
DJ	NULL
,	NULL
Chen	NULL
Y	NULL
and	NULL
Lee	NULL
WH	NULL
.	NULL

(	NULL
1996a	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
10	NULL
,	NULL
2794-2804	NULL
.	NULL

Chen	NULL
PL	NULL
,	NULL
Riley	NULL
DJ	NULL
,	NULL
Chen-Kiang	NULL
S	NULL
and	NULL
Lee	NULL
WH	NULL
.	NULL

(	NULL
1996b	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
465-469	NULL
.	NULL

Chen	NULL
Z	NULL
,	NULL
Brand	NULL
NJ	NULL
,	NULL
Chen	NULL
A	NULL
,	NULL
Chen	NULL
SJ	NULL
,	NULL
Tong	NULL
JH	NULL
,	NULL
Wang	NULL
ZY	NULL
,	NULL
Waxman	NULL
S	NULL
and	NULL
Zelent	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
1161-1167	NULL
.	NULL

Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
treated	NULL
at	NULL
day	NULL
0	NULL
with	NULL
«	NULL
1-PML	NULL
or	NULL
scrambled	NULL
«	NULL
1-PML	NULL
(	NULL
Ser	NULL
al-PML	NULL
)	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
Nuclear	NULL
extract	NULL
preparation	NULL
-	NULL
Nuclear	NULL
extracts	NULL
,	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
Snow	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
were	NULL
normalized	NULL
for	NULL
cell	NULL
number	NULL
from	NULL
4x	NULL
10°	NULL
HPCs	NULL
collected	NULL
at	NULL
day	NULL
9	NULL
and	NULL
11	NULL
of	NULL
E	NULL
culture	NULL
,	NULL
at	NULL
day	NULL
9	NULL
of	NULL
G	NULL
culture	NULL
,	NULL
or	NULL
from	NULL
2x	NULL
10°	NULL
cells	NULL
from	NULL
different	NULL
cell	NULL
lines	NULL
(	NULL
K562	NULL
and	NULL
Jurkat	NULL
,	NULL
for	NULL
positive	NULL
controls	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
expression	NULL
,	NULL
respectively	NULL
;	NULL
SAOS-2	NULL
for	NULL
negative	NULL
control	NULL
of	NULL
Rb	NULL
protein	NULL
expression	NULL
)	NULL
.	NULL

Immunoprecipitation	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Snow	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
with	NULL
(	NULL
i	NULL
)	NULL
anti-PML	NULL
mAb	NULL
,	NULL
PG-M3	NULL
used	NULL
at	NULL
1/50	NULL
dilution	NULL
(	NULL
Flenghi	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
or	NULL
with	NULL
(	NULL
ii	NULL
)	NULL
anti-pRb105	NULL
mAb	NULL
used	NULL
at	NULL
1/1000	NULL
dilution	NULL
(	NULL
Condorelli	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Several	NULL
controls	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
day	NULL
9	NULL
E	NULL
culture	NULL
:	NULL
(	NULL
i	NULL
)	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
hGATA-1	NULL
(	NULL
Labbaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
using	NULL
the	NULL
anti-	NULL
hGATA-1	NULL
mAb	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
,	NULL
to	NULL
assay	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
PML	NULL
/pRb	NULL
complex	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
addition	NULL
of	NULL
IgG	NULL
or	NULL
beads	NULL
alone	NULL
to	NULL
evaluate	NULL
background	NULL
in	NULL
the	NULL
immunoprecipitation	NULL
procedure	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
Immune	NULL
complex	NULL
samples	NULL
were	NULL
prepared	NULL
in	NULL
duplicate	NULL
and	NULL
loaded	NULL
onto	NULL
two	NULL
different	NULL
8	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
.	NULL

Blotted	NULL
membranes	NULL
were	NULL
probed	NULL
:	NULL
(	NULL
i	NULL
)	NULL
first	NULL
,	NULL
with	NULL
anti-PML	NULL
mAb	NULL
,	NULL
PG-M3	NULL
diluted	NULL
1/500	NULL
or	NULL
with	NULL
the	NULL
anti-pRb105	NULL
polyclonal	NULL
antibody	NULL
,	NULL
SC-15	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
diluted	NULL
1/5000	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
After	NULL
stripping	NULL
,	NULL
the	NULL
membrane	NULL
first	NULL
treated	NULL
with	NULL
anti-PML	NULL
,	NULL
was	NULL
reprobed	NULL
with	NULL
anti-pRb105	NULL
polyclonal	NULL
Ab	NULL
,	NULL
SC-15	NULL
and	NULL
the	NULL
membrane	NULL
first	NULL
treated	NULL
with	NULL
the	NULL
anti-pRb105	NULL
was	NULL
reprobed	NULL
with	NULL
anti-PML	NULL
mAb	NULL
.	NULL

Blots	NULL
were	NULL
visualized	NULL
by	NULL
Enhanced	NULL
Chemiluminescence	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Condorelli	NULL
G	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Valtieri	NULL
M	NULL
,	NULL
Vitelli	NULL
L	NULL
,	NULL
De	NULL
Luca	NULL
A	NULL
,	NULL
Barberi	NULL
T	NULL
,	NULL
Montesoro	NULL
E	NULL
,	NULL
Campisi	NULL
S	NULL
,	NULL
Giordano	NULL
A	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
,	NULL
4808	NULL
4812	NULL
.	NULL

Daniel	NULL
MT	NULL
,	NULL
Koken	NULL
M	NULL
,	NULL
Romagne	NULL
O	NULL
,	NULL
Barbey	NULL
S	NULL
,	NULL
Bazarbachi	NULL
A	NULL
,	NULL
Stadler	NULL
M	NULL
,	NULL
Guillemin	NULL
MC	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Chomienne	NULL
C	NULL
and	NULL
de	NULL
Thé	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
82	NULL
,	NULL
1858-1867.	NULL
de	NULL
The	NULL
H	NULL
,	NULL
Lavau	NULL
C	NULL
,	NULL
Marchio	NULL
A	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Degos	NULL
L	NULL
and	NULL
Dejean	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
,	NULL
675-684	NULL
.	NULL

Doucas	NULL
V	NULL
,	NULL
Ishov	NULL
AM	NULL
,	NULL
Romo	NULL
A	NULL
,	NULL
Juguilon	NULL
H	NULL
,	NULL
Weitzman	NULL
MD	NULL
,	NULL
Evans	NULL
RM	NULL
and	NULL
Maul	NULL
GG	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
10	NULL
,	NULL
196-207	NULL
.	NULL

Dyck	NULL
JA	NULL
,	NULL
Maul	NULL
GG	NULL
,	NULL
Miller	NULL
Jr	NULL
WH	NULL
,	NULL
Chen	NULL
JD	NULL
,	NULL
Kakizuka	NULL
A	NULL
and	NULL
Evans	NULL
RM	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
76	NULL
,	NULL
333-343	NULL
.	NULL

Everett	NULL
RD	NULL
and	NULL
Maul	NULL
GG	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
5062-5069	NULL
.	NULL

Everett	NULL
RD	NULL
,	NULL
Meredith	NULL
M	NULL
,	NULL
Orr	NULL
A	NULL
,	NULL
Cross	NULL
A	NULL
,	NULL
Kathoria	NULL
M	NULL
and	NULL
Parkinson	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
16	NULL
,	NULL
1519-1530	NULL
.	NULL

Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Venturini	NULL
L	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Simeone	NULL
A	NULL
,	NULL
Acampora	NULL
D	NULL
,	NULL
Grignani	NULL
F	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
7	NULL
,	NULL
1083-1091	NULL
.	NULL

Flenghi	NULL
L	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Tomassoni	NULL
L	NULL
,	NULL
Pileri	NULL
S	NULL
,	NULL
Gambacorta	NULL
M	NULL
,	NULL
Pacini	NULL
R	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Casini	NULL
T	NULL
,	NULL
Ferrucci	NULL
PF	NULL
,	NULL
Martelli	NULL
MF	NULL
,	NULL
Pelicci	NULL
PG	NULL
and	NULL
Falini	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
85	NULL
,	NULL
1871-1880	NULL
.	NULL

Gabbianelli	NULL
M	NULL
,	NULL
Sargiacomo	NULL
M	NULL
,	NULL
Pelosi	NULL
E	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Isacchi	NULL
G	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
249	NULL
,	NULL
1561-1564	NULL
.	NULL

Giampaolo	NULL
A	NULL
,	NULL
Sterpetti	NULL
P	NULL
,	NULL
Bulgarini	NULL
D	NULL
,	NULL
Samoggia	NULL
P	NULL
,	NULL
Pelosi	NULL
E	NULL
,	NULL
Valtieri	NULL
M	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
84	NULL
,	NULL
3637-3647	NULL
.	NULL

Goddard	NULL
AD	NULL
,	NULL
Borrow	NULL
J	NULL
,	NULL
Freemont	NULL
PS	NULL
and	NULL
Solomon	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
254	NULL
,	NULL
1371-1374	NULL
.	NULL

3539	NULL
Expression	NULL
and	NULL
role	NULL
of	NULL
PML	NULL
and	NULL
Rb	NULL
proteins	NULL
in	NULL
erythropoiesis	NULL
C	NULL
Labbaye	NULL
et	NULL
al	NULL
3540	NULL
Grignani	NULL
F	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Longo	NULL
L	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Donti	NULL
E	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
Lo	NULL
Coco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
83	NULL
,	NULL
10-25	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Ferrucci	NULL
PF	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Talamo	NULL
G	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Peschle	NULL
C	NULL
,	NULL
Nicoletti	NULL
I	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
74	NULL
,	NULL
423-431	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Barberi	NULL
T	NULL
,	NULL
Masciulli	NULL
R	NULL
,	NULL
Mariani	NULL
G	NULL
,	NULL
Peschle	NULL
C	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
55	NULL
,	NULL
440-443	NULL
.	NULL

Grignani	NULL
F	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Rogaia	NULL
D	NULL
,	NULL
Ferrucci	NULL
PF	NULL
,	NULL
Samoggia	NULL
P	NULL
,	NULL
Pinto	NULL
A	NULL
,	NULL
Aldinucci	NULL
D	NULL
,	NULL
Gelmetti	NULL
V	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Seeler	NULL
J	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Nicoletti	NULL
I	NULL
,	NULL
Peschle	NULL
C	NULL
and	NULL
Pelicci	NULL
PG	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
15	NULL
,	NULL
4949-4958	NULL
.	NULL

Grisolano	NULL
JL	NULL
,	NULL
Wesselschmidt	NULL
RL	NULL
,	NULL
Pelicci	NULL
PG	NULL
and	NULL
Ley	NULL
TJ	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
89	NULL
,	NULL
376-387	NULL
.	NULL

Guiochon-Mantel	NULL
A	NULL
,	NULL
Savouret	NULL
JF	NULL
,	NULL
Quignon	NULL
F	NULL
,	NULL
Delabre	NULL
K	NULL
,	NULL
Milgrom	NULL
E	NULL
and	NULL
De	NULL
Thé	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
1791-1803	NULL
.	NULL

He	NULL
D	NULL
,	NULL
Mu	NULL
ZM	NULL
,	NULL
Le	NULL
X	NULL
,	NULL
Hsieh	NULL
JT	NULL
,	NULL
Pong	NULL
RC	NULL
,	NULL
Chung	NULL
LW	NULL
and	NULL
Chang	NULL
KS	NULL
.	NULL

(	NULL
1997a	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
,	NULL
1868-1872	NULL
.	NULL

He	NULL
LZ	NULL
,	NULL
Tribioli	NULL
C	NULL
,	NULL
Rivi	NULL
R	NULL
,	NULL
Peruzzi	NULL
D	NULL
,	NULL
Pelicci	NULL
PG	NULL
,	NULL
Soares	NULL
V	NULL
,	NULL
Cattoretti	NULL
G	NULL
and	NULL
Pandolfi	NULL
PP	NULL
.	NULL

(	NULL
1997b	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
5302-5307	NULL
.	NULL

Huang	NULL
ME	NULL
,	NULL
Ye	NULL
YC	NULL
,	NULL
Chen	NULL
SR	NULL
,	NULL
Chai	NULL
JR	NULL
,	NULL
Lu	NULL
JX	NULL
,	NULL
Zhoa	NULL
L	NULL
,	NULL
Gu	NULL
LJ	NULL
and	NULL
Wang	NULL
ZY	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
72	NULL
,	NULL
567-572	NULL
.	NULL

Kastner	NULL
P	NULL
,	NULL
Perez	NULL
A	NULL
,	NULL
Lutz	NULL
Y	NULL
,	NULL
Rochette-Egly	NULL
C	NULL
,	NULL
Gaub	NULL
MP	NULL
,	NULL
Durand	NULL
B	NULL
,	NULL
Lanotte	NULL
M	NULL
,	NULL
Berger	NULL
R	NULL
and	NULL
Chambon	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
629-642	NULL
.	NULL

Koken	NULL
MH	NULL
,	NULL
Puvion-Dutilleul	NULL
F	NULL
,	NULL
Guillemin	NULL
MC	NULL
,	NULL
Viron	NULL
A	NULL
,	NULL
Linares-Cruz	NULL
G	NULL
,	NULL
Stuurman	NULL
N	NULL
,	NULL
de	NULL
Jong	NULL
L	NULL
,	NULL
Szostecki	NULL
C	NULL
,	NULL
Calvo	NULL
F	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Puvion	NULL
E	NULL
and	NULL
deThé	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
1073-1083	NULL
.	NULL

Labbaye	NULL
C	NULL
,	NULL
Valtieri	NULL
M	NULL
,	NULL
Barberi	NULL
T	NULL
,	NULL
Meccia	NULL
E	NULL
,	NULL
Masella	NULL
B	NULL
,	NULL
Pelosi	NULL
E	NULL
,	NULL
Condorelli	NULL
GL	NULL
,	NULL
Testa	NULL
U	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
95	NULL
,	NULL
2346-2358	NULL
.	NULL

Labbaye	NULL
C	NULL
,	NULL
Valtieri	NULL
M	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Giampaolo	NULL
A	NULL
,	NULL
Meccia	NULL
E	NULL
,	NULL
Sterpetti	NULL
P	NULL
,	NULL
Parolini	NULL
I	NULL
,	NULL
Pelosi	NULL
E	NULL
,	NULL
Bulgarini	NULL
D	NULL
,	NULL
Cayre	NULL
YE	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
83	NULL
,	NULL
651-656	NULL
.	NULL

Liu	NULL
JH	NULL
,	NULL
Mu	NULL
ZM	NULL
and	NULL
Chang	NULL
KS	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
181	NULL
,	NULL
1965-1973	NULL
.	NULL

Mu	NULL
ZM	NULL
,	NULL
Chin	NULL
KV	NULL
,	NULL
Liu	NULL
JH	NULL
,	NULL
Lozano	NULL
G	NULL
and	NULL
Chang	NULL
KS	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
6858-6867	NULL
.	NULL

Nason-Burchenal	NULL
K	NULL
,	NULL
Gandini	NULL
D	NULL
,	NULL
Botto	NULL
M	NULL
,	NULL
Allopenna	NULL
J	NULL
,	NULL
Seale	NULL
JR	NULL
,	NULL
Cross	NULL
NC	NULL
,	NULL
Goldman	NULL
JM	NULL
,	NULL
Dmitrovsky	NULL
E	NULL
and	NULL
Pandolfi	NULL
PP	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
88	NULL
,	NULL
3926-3936	NULL
.	NULL

Nevins	NULL
JR.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
258	NULL
,	NULL
424-429	NULL
.	NULL

Perez	NULL
A	NULL
,	NULL
Kastner	NULL
P	NULL
,	NULL
Sethi	NULL
S	NULL
,	NULL
Lutz	NULL
Y	NULL
,	NULL
Reibel	NULL
C	NULL
and	NULL
Chambon	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
3171-3182	NULL
.	NULL

Rabbitts	NULL
TH	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
67	NULL
,	NULL
641-644	NULL
.	NULL

Reddy	NULL
BA	NULL
,	NULL
Etkin	NULL
LD	NULL
and	NULL
Freemont	NULL
PS	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
17	NULL
,	NULL
344-345	NULL
.	NULL

Redner	NULL
RL	NULL
,	NULL
Rush	NULL
EA	NULL
,	NULL
Faas	NULL
S	NULL
,	NULL
Rudert	NULL
WA	NULL
and	NULL
Corey	NULL
SJ	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
,	NULL
882-886	NULL
.	NULL

Rousselot	NULL
P	NULL
,	NULL
Hardas	NULL
B	NULL
,	NULL
Patel	NULL
A	NULL
,	NULL
Guidez	NULL
F	NULL
,	NULL
Gaken	NULL
J	NULL
,	NULL
Castaigne	NULL
S	NULL
,	NULL
Dejean	NULL
A	NULL
,	NULL
de	NULL
The	NULL
H	NULL
,	NULL
Degos	NULL
L	NULL
and	NULL
Farzaneh	NULL
F.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
9	NULL
,	NULL
545-551	NULL
.	NULL

Sawyers	NULL
CL	NULL
,	NULL
Denny	NULL
CT	NULL
and	NULL
Witte	NULL
ON	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
64	NULL
,	NULL
337	NULL
350	NULL
.	NULL

Shivdasani	NULL
RA	NULL
and	NULL
Orkin	NULL
SH	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
,	NULL
4025-4039	NULL
.	NULL

Snow	NULL
CM	NULL
,	NULL
Senior	NULL
A	NULL
and	NULL
Gerace	NULL
L.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
104	NULL
,	NULL
1143-1156	NULL
.	NULL

Taya	NULL
Y	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
22	NULL
,	NULL
14-17	NULL
.	NULL

Valtieri	NULL
M	NULL
,	NULL
Gabbianelli	NULL
M	NULL
,	NULL
Pelosi	NULL
E	NULL
,	NULL
Bassano	NULL
E	NULL
,	NULL
Petti	NULL
S	NULL
,	NULL
Russo	NULL
G	NULL
,	NULL
Testa	NULL
U	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
74	NULL
,	NULL
460	NULL
470	NULL
.	NULL

Valtieri	NULL
M	NULL
,	NULL
Venturelli	NULL
D	NULL
,	NULL
Caré	NULL
A	NULL
,	NULL
Fossati	NULL
C	NULL
,	NULL
Pelosi	NULL
E	NULL
,	NULL
Labbaye	NULL
C	NULL
,	NULL
Mattia	NULL
G	NULL
,	NULL
Gewirtz	NULL
AM	NULL
,	NULL
Calabretta	NULL
B	NULL
and	NULL
Peschle	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
,	NULL
1181-1190	NULL
.	NULL

Wang	NULL
ZG	NULL
,	NULL
Delva	NULL
L	NULL
,	NULL
Gaboli	NULL
M	NULL
,	NULL
Rivi	NULL
R	NULL
,	NULL
Giorgio	NULL
M	NULL
,	NULL
Cordon-Cardo	NULL
C	NULL
,	NULL
Grosveld	NULL
F	NULL
and	NULL
Pandolfi	NULL
PP	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
279	NULL
,	NULL
1547-1551	NULL
.	NULL

Warrell	NULL
Jr	NULL
RP	NULL
,	NULL
Frankel	NULL
SR	NULL
,	NULL
Miller	NULL
Jr	NULL
WH	NULL
,	NULL
Scheinberg	NULL
DA	NULL
,	NULL
Itri	NULL
LM	NULL
,	NULL
Hittelman	NULL
WN	NULL
,	NULL
Vyas	NULL
R	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Tafuri	NULL
A	NULL
,	NULL
Jakubowski	NULL
A	NULL
,	NULL
Gabrilove	NULL
J	NULL
,	NULL
Gordon	NULL
MS	NULL
and	NULL
Dmitrowski	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

New	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
324	NULL
,	NULL
1385-1393	NULL
.	NULL

Warrell	NULL
Jr	NULL
RP	NULL
,	NULL
de	NULL
The	NULL
H	NULL
,	NULL
Wang	NULL
ZY	NULL
and	NULL
Degos	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

New	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
329	NULL
,	NULL
177-189	NULL
.	NULL

Weis	NULL
K	NULL
,	NULL
Rambaud	NULL
S	NULL
,	NULL
Lavau	NULL
C	NULL
,	NULL
Jansen	NULL
J	NULL
,	NULL
Carvalho	NULL
T	NULL
,	NULL
Carmo-Fonseca	NULL
M	NULL
,	NULL
Lamond	NULL
A	NULL
and	NULL
Dejean	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
76	NULL
,	NULL
345-356	NULL
.	NULL

Wells	NULL
RA	NULL
,	NULL
Catzavelos	NULL
C	NULL
and	NULL
Kamel-Reid	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
17	NULL
,	NULL
109-113	NULL
.	NULL

